Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


With additional active ingredient

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514169000 - Cyclopentanohydrophenanthrene ring system DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045955NOVEL COMPOUNDS - The present invention provides compounds of formula (I)02-21-2013
20130045954ANTIMICROBIAL COMPOSITION - Antimicrobial compositions comprising a terpenoid in combination with an antimicrobial agent are provided. In addition, uses of such compositions in various applications involving preventing, combating or treating microbial infections, or preventing microbial growth or establishment are provided.02-21-2013
20130045956PREVENTIVE AND/OR THERAPEUTIC AGENT OF HAND-FOOT SYNDROME - The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.02-21-2013
20110178048STABILIZED FORMULATION OF TRIAMCINOLONE ACETONIDE - A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.07-21-2011
20080261934Dosage Form for Hormonal Contraception - A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 μg of folic acid and the daily units B contain >200 μg up to the maximum permissible amount of folic acid for women.10-23-2008
20090215733THERAPY FOR THE PROPHYLAXIS OR TREATMENT OF ADVERSE BODY COMPOSITION CHANGES AND/OR DECREASED MUSCLE STRENGTH AFTER ANDROGEN OR GNRH ANALOGUE INTAKE - Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or more effects after androgen or gonadotropin releasing hormone (GnRH) analogue intake comprises administering to a male subject at least one of a blocking compound which antagonizes estradiol binding to estradiol receptors or an inhibitor compound which inhibits endogenous production of estradiol, after androgen or gonadotropin releasing hormone (GnRH) analogue intake, to treat the one or more effects. The one or more effects include adverse body composition changes, decreased muscle strength, or both. The inhibitor compound and/or blocking compound may include antiestrogen agents, aromatase inhibitors, or combinations thereof.08-27-2009
20130029952Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.01-31-2013
20130029951Combination of Azelastine and Ciclesonide for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.01-31-2013
20130029950METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE VASCULAR DISORDERS - The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.01-31-2013
20090029956Substance mixture - A substance mixture comprising at least one glucocorticoid and at least one N-chloro compound and/or at least one O-chloro compound as well as a medicament containing such a substance mixture as well as the use and manufacture of such a medicament for the topical treatment of inflammations.01-29-2009
20100087407 USE OF AROMATASE INHIBITORS - The invention provides a method of thinning the endometrium in a woman by utilizing a therapeutically effective amount of an aromatase inhibitor.04-08-2010
20120184519Compositions and Methods for Preventing or Treating Influenza Virus Infection - The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.07-19-2012
20120184518METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS - Methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, sepsis and peritonitus. Further provided are respective diagnostic methods, assays and kits.07-19-2012
20120184517TREATMENT OF DISEASES WITH ALTERED SMOOTH MUSCLE CONTRACTILITY - The present invention provides, inter alia, methods and compositions for treating or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma.07-19-2012
20120184516sGC Stimulators - Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.07-19-2012
20100160273CONTROLLED DELIVERY SYSTEM OF ANTIFUNGAL AND KERATOLYTIC AGENTS FOR LOCAL TREATMENT OF FUNGAL INFECTIONS OF THE NAIL AND SURROUNDING TISSUES - A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifungal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent or combination thereof. The composition may further include an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof.06-24-2010
20090312295Second line treatment of metastatic hormone refractory prostate cancer using satraplatin - The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 212-17-2009
20100160269Use of N-(dibenz(B,F)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy - The invention relates to the use of a compound of the formula (I)06-24-2010
20090192129BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I)07-30-2009
20090192127Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment - The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and an PI3K/AKT signaling pathway inhibitor The PI3K/AKI signaling pathway inhibitor comprises PI3 inhibitors {like celecoxilo, viridins, wortmannins}, AKT kinase inhibitors {like perifosine, triciribine} and mTOR inhibitors {like the rapamycins temsirolimus and evorolimus}.07-30-2009
20090192128GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM - The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.07-30-2009
20110195943NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR - The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.08-11-2011
20130029948HETEROCYCLIC AUTOTAXIN INHIBITORS AND USES THEREOF - Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.01-31-2013
20130029949Substituted Quinolines and Their Use As Medicaments - Disclosed are substituted quinolines of formula 101-31-2013
20090075956Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 - The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.03-19-2009
20130085124USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COMMON COLD AND INFLAMMATION - The embodiments described herein include methods and formulations for treating influenza, common cold and associated acute inflammation. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.04-04-2013
20130085122BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS - The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.04-04-2013
20090203658NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE THEREFOR - Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), progesterone (PROG), precursors thereof, metabolites thereof, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.08-13-2009
201000759345-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR - Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.03-25-2010
20100075935XANTHINE MODULATORS OF ADENOSINE A1 RECEPTOR - The present invention relates to new xanthine modulators of adenosine A03-25-2010
20120245132Composition Comprising Benzoic Acid in Combination with Organic Acid Preservatives as Active Ingredients and the Use Thereof - The present invention relates to the use of low content of benzoic acid and/or sodium salt thereof in combination with one or more organic acid preservatives as active ingredients in the manufacture of a vaginal composition, wherein the composition has weak inhibition effect on normal vaginal lactobacilli while has strong inhibition effect on vaginal fungi and/or pathogenic vaginal lactobacilli, the organic acid preservatives are selected from the group consisting of dehydroacetic acid and/or sodium salt thereof, propionic acid and/or a salt thereof, sorbic acid and/or a salt thereof. The composition of the present invention is particularly useful in inhibiting vaginal fungi, and/or inhibiting pathogenic vaginal lactobacilli, and/or promoting normal vaginal lactobacilli, and/or maintaining normal vaginal acidity, and/or modulating vaginal microecosystem, and/or modulating vaginal microbials, and/or selectively decontaminating vagina.09-27-2012
20090075957XANTHOHUMOL COMPOSITIONS AND METHODS OF USING SAME - The present invention provides compositions comprising an effective amount of xanthohumol and honokiol. The present invention comprises compositions comprising an effective amount of xanthohumol and genistein. The present invention comprises compositions comprising an effective amount of xanthohumol and guggulsterone. The compositions of the present invention may be effective to decrease mature adipocytes viability, induce apoptosis of mature adipocytes, increase lipolysis in mature adipocytes, and/or reduce adipogenesis during the maturation of pre-adipocytes. The present invention further provides methods of treating obesity, diabetes, osteoporosis or bone disorders in a subject, which comprise administering to the subject compositions comprising an effective amount of xanthohumol and honokiol, guggulsterone, or genistein.03-19-2009
20130079314ALOE VERA EXTRACT, METHOD OF PRODUCING ALOE VERA EXTRACT, AND HYPERGLYCEMIA IMPROVING AGENT - The present invention provides: an 03-28-2013
20130079312Method of Treating Hair Loss Due to Systemic Chemotherapy - Methods and composition for preventing and/or treating hair loss associated with the administration of cancer chemotherapy using vasoconstrictors are disclosed. Optionally corticosteroids are also in the formulation.03-28-2013
20130085123ORGANIC COMPOUNDS - Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.04-04-2013
20130035320PYRROLIDINE DERIVATIVES - Novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formulae (I) and (I′) are effective for the prevention and/or treatment of diseases in which the number, activity, and movement of inflammatory cells is implicated.02-07-2013
20130035319COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane. In the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.02-07-2013
20130035318C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III:02-07-2013
20130040920COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL - The present invention is a method for obtaining a formulation of resveratrol and rice bran oil. The resulting product in the form of an oil or solid proves to increase the therapeutic potential of resveratrol by the synergistic action of the components of the rice oil.02-14-2013
20130079313DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.03-28-2013
20090291928COMPOSITION FOR AMELIORATION/PREVENTION OF ADVERSE SIDE EFFECT IN STEROID THERAPY - Provided is a composition containing isoleucine, leucine and valine as active ingredients for improving or suppressing side effects associated with a steroid treatment and a composition for suppressing muscular atrophy-related gene. The composition improves or suppresses side effects in a steroid treatment such as muscular atrophy, muscular pain, arthritic pain, impaired glucose tolerance, decreased bone metabolism, impaired immunity, loss of appetite, body weight loss, fatigability and the like, and further suppresses muscular atrophy associated with various diseases. In addition, the composition suppresses muscular atrophy associated with promoted expression of muscular atrophy-related gene associated with glucocorticoid excess or renal failure pathology and the like. Therefore, the composition is effective form improving the QOL of patients.11-26-2009
20100099651PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS - The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK04-22-2010
20100099652NOVEL COMPOSITION BASED ON CHOLEST-4-EN-3-ONE OXIME - A subject of the invention is a novel composition, particularly a pharmaceutical composition comprising cholest-4-en-3-one oxime and an oil chosen from sesame oil, olive oil, soya oil, cotton oil, or a mixture of commercial medium-chain triglycerides (ESTASAN®, MYGLIOL®), or a mixture of these oils, preferably sesame oil, olive oil or soya oil, even more preferably sesame oil.04-22-2010
20100099650NASAL SPRAY COMPOSITION AND METHOD FOR TREATING RHINITIS, SINUSITIS OR BOTH - A nasal spray composition for treating mucosal inflammation associated with rhinitis, sinusitis, or both can include a decongestant and at least one therapeutic agent. The therapeutic agent is selected from the group consisting of an anti-inflammatory agent and an anti-histamine agent. The nasal spray composition is non-habituating and is administered intranasally to a subject in need thereof.04-22-2010
20100137268PHTHALAZINONE MODULATORS OF H1 RECEPTORS AND/OR LTC4 RECEPTORS - The present invention relates to new phthalazinone modulators of H1 receptor activity and/or modulators of LTC4 production, pharmaceutical compositions thereof, and methods of use thereof.06-03-2010
20100323999Therapeutic Molecules and Methods-1 - Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy. Novel heterocyclic compounds are also provided for.12-23-2010
20100041632USES OF THE CARBOXY-AMIDO-TRIAZOLE COMPOUNDS AND SALTS THEREOF - The present invention relates to new medical use of CAI and its analogs/derivates together with the pharmaceutically acceptable salts thereof. Particularly, the use of CAI and its analogs/derivates, together with pharmaceutically acceptable salts thereof as TNF-α and IL-1β inhibitor and the use of these compounds in preparation of formulations for treatment of TNF-α and/or IL-1β mediated diseases other than malignant tumor especially of painful diseases and/or inflammatory diseases are provided herein.02-18-2010
20090156566METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.06-18-2009
20090156565COMPOSITION AND USE THEREOF IN ENHANCING A THERAPEUTIC EFFECT OF AN ANTIEPILEPTIC DRUG - A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition includes a glucocorticoid receptor antagonist and an antiepileptic drug, wherein the glucocorticoid receptor antagonist is present in an amount effective to enhance a therapeutic effect of the antiepileptic drug in treating a seizure in a status-epilepticus in an animal. A method of use of a glucocorticoid receptor antagonist for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal, the method includes administering the glucocorticoid receptor antagonist and the antiepileptic drug, wherein the glucocorticoid receptor antagonist is administered to the animal prior to, contemporaneous with, or subsequent to administering the antiepileptic drug in an amount effective to enhance the therapeutic effect of the antiepileptic drug.06-18-2009
20100105643Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range.04-29-2010
20100105644BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF - A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion of damaged skin, a composition comprising a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier.04-29-2010
20100105642NOVEL COMPOUNDS 409 - The present invention provides a compound of formula (I)04-29-2010
20090062246THERAPEUTIC TREATMENT-014 - A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an aromatase inhibitor or an estrogen receptor down-regulator is described. The combination is expected to be useful in the treatment of cancer.03-05-2009
20090149428Methods for Assessing the Predisposition or Susceptibility to COPD - This invention relates to novel associations between polymorphisms in the genes encoding the human Epithelial Na+ Channel (ENaC) and COPD. More particularly, the invention relates to a method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises detecting the presence of a polymorphism in one or more human ENaC-encoding genes, in particular position 06-11-2009
20100160272OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION - The present invention relates to new oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100029601Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy - Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.02-04-2010
201003312876-(Aminoalkyl)Indazoles - 6-(Aminoalkyl)indazoles of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, and renal, cardiac and vascular protecting medicinally active ingredients.12-30-2010
20100093683METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH A PROTEASOME INHIBITOR - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.04-15-2010
20090312294Method and Agent for Reducing Weight, Accelerating Lipid Catabolism, and/or Restricting Calories - A method and an agent for reducing weight, accelerating lipid catabolism, and/or restricting calories includes a preparation having chrysin and cholic acid for producing a medicament.12-17-2009
20120165302ANTIFUNGAL FORMULATIONS - A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis.06-28-2012
20090221540Method of Treating An Acute Vascular Disorder - The invention relates to a method of treating an acute vascular disorder in a mammal. The method comprises orally administering to the mammal an effective amount of a steroid. The steroid is selected from the group consisting of: substances represented by formula (I), in which R09-03-2009
20090325914Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy - Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.12-31-2009
20090306028COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and an anti-inflammatory agent.12-10-2009
20090306027GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM - The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.12-10-2009
20090306026Pharmaceutical Formulations and Uses Thereof in the Treatment of Female Sexual Dysfunction - The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analogue thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.12-10-2009
20120309726COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.12-06-2012
20110015164METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS - A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the ‘insulin resistance syndrome’, and ‘syndrome X’), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural formula I, II, III, or IV is disclosed. The method is also concerned with the use of the 5alpha reductase inhibiting compound together with antidiabetic agents, lipid lowering agents, antihypertensive agents, antiobesity agents, testosterone, testosterone precursors, testosterone prodrugs, testosterone analogs, and other androgen receptor agonists for treating visceral adiposity, metabolic syndrome, type II diabetes and insulin resistance in men.01-20-2011
20110015163CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND - The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.01-20-2011
20110065678ISOXAZOLIDINE DERIVATIVES - Novel glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds.03-17-2011
20090270355Compounds - The present invention relates to a compound which is N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide10-29-2009
20120225851COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES - The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.09-06-2012
20120225850Steroidal antitubercular compounds - A steroidal compound n-hexyl-p-stigmasteryloxy-benzoate is reported as a novel potent antitubercular drug.09-06-2012
20130065870TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.03-14-2013
20130065869OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD - Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.03-14-2013
20090264389Method of preparing dry powder inhalation compositions - The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.10-22-2009
20090029955Pyridothienopyrimidine Derivatives - A pyridothienopyrimidine derivative of formula (I),01-29-2009
20090253664COMBINATION ANDOLAST/GLUCOCORTICOIDS - The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical compositions comprising Andoalst and glucocorticoids are also disclosed.10-08-2009
20120232044METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA - Methods and compositions for treating and/or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.09-13-2012
20090012051EXTERNAL PREPARATION - The present invention provides an external preparation which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1′-cyclopentane] represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, comprising 0.5 to 15% by mass of a solvent component in which the solubility of the active ingredient is 4 mg/mL or more, and the like.01-08-2009
20090012050Quinone Derivative 2,3-Dimethoxy-5-Methyl-6-(10-Hydroxydecyl)-1,4-Benzoquinone for the Treatment of Muscular Dystrophies - Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.01-08-2009
20120238532TREATMENT OF HUMAN OSTEOSARCOMA - The present invention describes the combination of cucurbitacin (CuB) with methotrexate (MTX) for the treatment of cancers, including osteosarcoma. It was discovered that CuB and MTX have synergistic activity against osteosarcoma, which reduces toxicities associated with both chemotherapeutic agents. The present invention also describes the use of CuB for the treatment of osteosarcoma.09-20-2012
20120101073Novel Method For Treating Breathing Disorders or Diseases - The present invention includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (+)-doxapram or a salt thereof, and a pharmaceutically acceptable carrier, wherein the formulation is essentially free of (−)-doxapram or a salt thereof.04-26-2012
20090099147NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS - The present invention relates to non-steroidal progesterone receptor modulators of the general formula I04-16-2009
20110281832ORGANIC COMPOUNDS - Optionally substituted (5- or 7-amino)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(6H)-ones, Compounds of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.11-17-2011
20110281833Composition for the Treatment of Ear Infections and Method - A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing such composition includes dissolving the antifungal agent, steroidal anti-inflammatory agent, and acid in dehydrated alcohol, dissolving the antibiotic agent in propylene glycol, combining the two solutions together, heating the combination and then cooling the composition. Several drops of the composition are applied at least twice per day to the affected area of the animal's ear.11-17-2011
20090111780COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION - The present invention relates to compositions and methods for treatment of ear infections and inflammation. Specifically, the method involves administering to a patient a composition containing an antibacterial, an anti-inflammatory, and an anti-septic that is substantially free of pramoxine to treat the occurrence or negative effects of otic infection and inflammation.04-30-2009
20100240624Ophthalmic Formulations of Ketotifen and Methods of Use - The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof.09-23-2010
20110144070DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.06-16-2011
20100267681FAT OR OIL COMPOSITION - A fat or oil composition containing the following ingredients (A) and (B): 10-21-2010
20110082124DETERGENT COMPOSITIONS FOR TREATMENT OF LIPOMAS AND OTHER CONDITIONS - A method of treating a lipoma involves contacting the lipoma with a detergent to dissolve the lipoma. For example, the detergent may be a cholate, deoxycholate or similar detergent. A method of treating cellulite and extra fat deposits involves contacting them with a detergent to help the dissolving of the fat tissues. A method of improving the art of lipoma and extra fat removal involves using certain detergents and controlling the pH, ionic forces and/or other factors to improve detergent action.04-07-2011
20080242649New Combination 665 - The invention provides a pharmaceutical product comprising a first active ingredient which is N—[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)—(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, 3(R)—1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)—3-[(2S)—2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.10-02-2008
20090221541PHARMACEUTICAL FORMULATIONS - An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures thereof.09-03-2009
20100240625Ophthalmic Formulations of Cetirizine and Methods of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.09-23-2010
20100120733STEROID MODULATORS OF GLUCOCORTICOID RECEPTOR - The present invention relates to new steroid modulators of glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20110301134ALKYNE ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.12-08-2011
20110301133COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS - The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.12-08-2011
20110301132METHODS OF TREATING URETHRITIS AND RELATED INFECTIONS USING FUSIDIC ACID - Methods for the treatment and prevention of a bacterial infection caused by 12-08-2011
20120004201PHOSPHODIESTARASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided.01-05-2012
20090143344METHODS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - The present invention relates to methods for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one receptor selected from the group consisting of a serotonin type 2A (5-HT06-04-2009
20090105200Combination therapy - The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided.04-23-2009
20080300225PESTICIDAL FORMULATION CONTAINING OXYMATRINE OR MATRINE - Compositions and methods are provided for a water-soluble insecticidal or pesticidal comprising at least one alkaloid, particularly at least one tetracyclo-quinolizindine alkaloid derived from sophora roots, particularly matrine and/or oxymatrine.12-04-2008
20100210611COMBINATION THERAPY - The present invention provides inhalation compositions comprising montelukast acid and a second active agent selected from a PDE4 inhibitor and an inhaled corticosteroid. Also provided is a method for the treatment of respiratory disorders such as asthma using such compositions.08-19-2010
20120015918Lipolytic Methods for Regional Adiposity - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.01-19-2012
20110294768Ophthalmic Suspension for Ocular Use - A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries.12-01-2011
20110294767BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.12-01-2011
20090253663SKIN EXTERNAL PREPARATION CONTAINING TRITERPENIC ACID - Disclosed is a skin external preparation containing a triterpenic acid typified by ursolic acid. For obtaining a skin external preparation having excellent storage stability by improving the dissolution stability of the triterpenic acid and the like, 4-alkylresorcinol such as 4-n-butylresorcinol is added into a skin external preparation containing a triterpenic acid and the like such as benzyl ursolate.10-08-2009
20110190248CYCLOHEXYLOXY SUBSTITUTED HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM - The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I)08-04-2011
20080318912Medicaments for Treating Chronic Respiratory Disease - There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease.12-25-2008
20090099148COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.04-16-2009
20100261687SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS - Object of the present invention are novel substituted compounds of the formula 1,10-14-2010
20110263550THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below:10-27-2011
20100113405METHYLINDAZOLE MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new methylindazole modulators of 5-HT3 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20090149430COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT - The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament.06-11-2009
20100267683PHARMACEUTICAL COMPOSITION COMPRISING PEROXIDED OIL AND CHOLESTEROL AND USES THEREOF IN MEDICAL FIELD - The present invention concerns a pharmaceutical composition comprising peroxided oil and cholesterol to be used in medical field, for example, in the treatment of tumours, viral diseases, ulcers and dermatitis.10-21-2010
20100267682CORTICOSTEROIDS TO TREAT EPOTHILONE OR EPOTHILONE DERIVATIVE INDUCED DIARRHEA - Epothilone derivatives are co-administered with an antidiarrheal agent, e.g., a corticosteroid, or a glucocorticoid steroid in the treatment of a proliferative disease.10-21-2010
20110201583GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I:08-18-2011
20110201582METHOD AND COMPOSITION FOR TREATMENT OF SKIN CONDITIONS - A method for treating dermatological conditions as eczema, seborrheic dermatitis, psoriasis and allergic skin reactions such as hives, skin irritations, poison ivy, poison oak, and the like. The method involves applying to the affected area of the skin a few drops of a combination of pheniramine maleate and either naphazoline HCL or phenylephrine HCL and then applying to the same affected area a topical corticosteroid cream, ointment or lotion. The preferred ratio is approximately one drop of solution for every approximately 0.1 grams of topical corticosteroid cream applied to each patch of skin affected with any of the dermatological conditions.08-18-2011
20090149429ANTIVIRAL COMPOUNDS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.06-11-2009
201102635494-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS - The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R10-27-2011
201001207306-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS - The compounds of formula (I)05-13-2010
20100016266Pyridine Imidazoles and Aza-indoles as Progesterone Receptor Modulators - The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.01-21-2010
20120065174COMPOSITIONS OF GLYCOPYRRONIUM SALT FOR INHALATION - A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.03-15-2012
20120035145METHODS OF TREATING MULTIPLE MYELOMA USING MELPHALAN, PREDNISONE AND LENALIDOMIDE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.02-09-2012
20100120734FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.05-13-2010
201001207313-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES - New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.05-13-2010
20100087408NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.04-08-2010
20100087410ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS - The invention provides novel β04-08-2010
20120108556METHODS AND DOSAGE FORMS FOR THE TREATMENT OF HUMAN CANCERS - Methods for the treatment of human cancers, daily dosage forms for cancer patients, and methods of formulating the dosage forms are provided wherein the daily dosage form contains from about 10-6,000 mg of each of β-sitosterol, isovanillin, and linolenic acid. Preferably, the dosage forms are formulated by first creating an aqueous decoction of 05-03-2012
20120108555Mixtures or Organic Compounds for the Treatment of Airway Diseases - A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.05-03-2012
20110201581Novel Compounds 010 - The present invention provides compounds of formula (I)08-18-2011
20120083478CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND - The invention relates to crystalline oxalate salts of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-methyl}phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester. This invention also relates to compositions containing such a crystalline oxalate salt; methods of using such a crystalline oxalate salt to, for example, treat a pulmonary disorder; and to processes for preparing such a crystalline oxalate salt.04-05-2012
20090143343COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.06-04-2009
20100249081COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE - The invention relates to methods, compositions, and kits for the treatment of proteinuria and/or hypertension (e.g., proteinuria and/or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and/or epleronone).09-30-2010
20090258846Eyebrow re-growth stimulator for re-growth of lost eyebrows - A chemical composition and method of an eyebrow re-growth stimulator for women who has lost there eyebrows due to dease and treatments. The lose of harmons and other causes such as in ageing women population. The eyebrow regrowth composition methods of topical treatment in an effective amount of the treatment which emploes a vasodilator in combination with estradiol and/or a 5-a-reductase inhibitor in a pharmaceutically acceptable vehicle. The compositions and methods of the invention are suitable for the treatment of lost eyebrows whereby the promotion of re-growth is increased.10-15-2009
20120295879NK1 Antagonists - A compound having the general structure shown in Formula I:11-22-2012
20090143345THIOAMIDE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS - Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.06-04-2009
20090286761Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device - A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).11-19-2009
20090088409SERUM BIOMARKERS FOR EARLY DETECTION OF ACUTE CELLULAR REJECTION - The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. A kit and methods of treating a subject having an organ transplant for ACR and treating an immune suppressed subject are also provided.04-02-2009
20080207572Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma - The present invention relates to a method for treating Multiple Myeloma (MM), FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual C-KIT/FGFR3 inhibitor, such as 2-aminoarylthiazoles and 2-aminoaryloxazoles.08-28-2008
20100279990ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR11-04-2010
20100279991TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS - This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I):11-04-2010
20090275541Method for treating neurocognitive dysfunction - A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment. Formula I is:11-05-2009
20080214513METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.09-04-2008
20090281069ORGANIC COMPOUNDS - The present invention relates to compounds of the formula;11-12-2009
20090286763AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF - The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.11-19-2009
20090042845Suppression and prevention of tumors - Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in finished products, especially with support of tests demonstrating the effectiveness of the treatment for, e.g., preventing tumors in populations known to be at risk of developing tumors, or, treating existing cancers in combination with other cancer drugs such as anastrozole and/or fulvestrant and/or artemisinin either concurrently or sequentially to prevent the cancer from growing when the cancer drug is not being used, the combination of betaine and Vitamin C optionally being supplemented or replaced by other treatments like the combination of selenium and Vitamin E or hormone treatments used to slow cancer growth.02-12-2009
20090042843Inhalation Device Containing Plural Doses of a Pharmaceutical Composition - The invention relates to an inhalation device comprising plural of doses of a pharmaceutical composition in powder form, wherein the pharmaceutical composition comprises one or more, preferably one, anticholinergic, optionally in combination with a pharmaceutically acceptable excipient.02-12-2009
20120289488Steroid-Sparing Effects of Beta-Adrenergic Inverse Agonists and Uses Thereof - Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory disease or condition, said method comprises simultaneously, concurrently, separately or sequentially administering to the patient an effective amount of a b-adrenergic receptor antagonist and a corticosteroid.11-15-2012
20120289489NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF - Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.11-15-2012
20100113404ANTI-ANGIOGENIC ACTIVITY OF 2-METHOXYESTRADIOL ANALOGS IN COMBINATION WITH ANTI-CANCER AGENTS - The present invention relates generally to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with anti-cancer agents. More specifically, the present invention relates to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol analogs, in combination with anti-cancer agents.05-06-2010
20090170823Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception - The present invention is directed to dosage regimens for emergency contraception using nonsteroidal progestins and pharmaceutical compositions and packages thereof. Such regimens are useful for females in need of emergency contraception.07-02-2009
20100137267FORMULATIONS FOR TREATMENT OF ADIPOSE TISSUE, CUTANEOUS TISSUE AND DISORDERS, AND MUSCULAR TISSUE - Compositions, formulations, methods, and systems for treating regional fat deposits and fat-related conditions, dermal conditions, and muscular conditions. Methods comprise administering a composition comprising at least one compound that reduces desensitization of beta adrenergic receptors, for example a glucocorticosteroid, and/or at least one long-acting beta-2 adrenergic receptor agonist, for example, formoterol. Compositions to be administered include sustained release formulations comprising at least one long-acting beta-2 adrenergic receptor agonist, at least one compound that reduces desensitization of beta adrenergic receptors, or both in a sustained crystalline microparticle form.06-03-2010
20080300227Drugs for treating hypertension combined with hyperuricemia and/or hypercholesterolemia - The invention is directed to a drug for treating hypertension combined with serum hyperuricemia and/or hypercholesterolemia, with the active ingredients being 2-propyl-3-{[21-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-5,6,7, 8-tetrahydrocyclohepta imidazole-4-(3H)-one and a prodrug or salt thereof. Pratosartan can be used in combination with one or more diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan can be used in combination with one or more hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.12-04-2008
20080280863COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention features methods and compositions for the treatment of immunoinflammatory disorders.11-13-2008
20080287405Compositions and Methods Relating to Protein Kinase Inhibitors - The present invention relates to compounds useful for treating fibrotic disorders, methods for their discovery, and their therapeutic use. In particular, the present invention provides pyrazolopyrimidine compounds and related compounds and methods of using pyrazolopyrimidine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with fibrotic disorders.11-20-2008
20080306035Methods and Compositions for Treating Female Infertility Using Clomiphene - The present invention relates to the use of compositions comprising clomiphene for treating female infertility. The invention is also directed to a regimen of treatment for female infertility using trans-clomiphene, a mixture of cis- and trans-clomiphene, and cis-clomiphene.12-11-2008
20080306036Triphenylethylene Compounds Useful as Selective Estrogen Modulators - Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.12-11-2008
20080242650Oral contraceptive regimen - A monophasic method of achieving contraception in a human female comprising orally administering to the human female a composition comprising 1.5 mg of 17-beta-estradiol and 2.5 mg of nomegestrol acetate for 24 days followed by a hormone-free period of 4 days.10-02-2008
20130217657COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS - Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.08-22-2013
20120046258NOVEL CRYSTALLINE PHARMACEUTICAL PRODUCT - There are provided crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I):02-23-2012
20090312296ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES - The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis.12-17-2009
20080207573COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.08-28-2008
20090264388Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells - The present invention relates to neurokinin-1 (NK-1) receptor antagonists in combination with an inhibitor of metachromatic cell activation, such as an anti-inflammatory agent, an immunosuppressor, or a kinase inhibitor, and use of such combinations in the treatment of disorders associated with activation of metachromatic cells. Disorders associated with the activation of metachromatic cells include allergic/non-allergic rhinitis, allergic/non-allergic asthma, allergic/non-allergic urticaria, immuno-inflammatory disorders, metachromatic cell-related autoimmune disorders, transplant rejection, and other metachromatic cell-related disorders.10-22-2009
20090264390Topical Personal Care Compositions And Methods of Use - Topical personal care compositions comprising an anti-inflammatory agent, a surfactant, a bodifier/humectant, and water and methods of use are disclosed.10-22-2009
20100137266TREATMENT OF INSULIN RESISTANCE AND DISORDERS ASSOCIATED THEREWITH - The present invention provides the use of an LXR antagonist, or a physiologically-acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is a compound being an ester or carbamate of a hydroxycholesterol, a pharmaceutical composition of such a compound or its use in therapy.06-03-2010
20120196840Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections - Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections.08-02-2012
200900299578-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS - The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula I01-29-2009
20090029958PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS - The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.01-29-2009
20090163455AVERMECTIN/HYDROCORTISONE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.06-25-2009
20090137539TOPICAL OPHTHALMIC OR OTIC SOLUTION FORMULATIONS CONTAINING MOXIFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE PHOSPHATE - Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.05-28-2009
20120071452COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.03-22-2012
20110224178Composition and method for treating erectile dysfunction - Erectile dysfunction in a male human patient is ameliorated by oral administration to the patient of a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil, and a glucocorticoid such as prednisone.09-15-2011
20090048219ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.02-19-2009
20090005352Prodrugs of Propofol, Compositions and Uses Thereof - The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.01-01-2009
20080318913Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.12-25-2008
20100004216Medicinal lipolysis of accumulation of fat - Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads.01-07-2010
20100004215COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS - Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.01-07-2010
200903259165-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS - Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.12-31-2009
20130217658PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS - The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.08-22-2013
20110144069COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.06-16-2011
20090054383Pharmaceutical compositions - Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.02-26-2009
20090062247METHODS FOR INHIBITING TGF-beta - The present invention provides methods for inhibiting or blocking TGF-β activity in cells and/or tissues expressing TGF-β comprising, contacting cells and/or tissues expressing TGF-β with an amount of cholesterol or cholesterol derivative effective to inhibit the activity of TGF-β. The present invention further provides a method for treating a condition associated with overactivity of TGF-β or negative regulation in normal physiology by TGF-β in a subject in need of treatment, comprising contacting cells and/or tissue overexpressing TGF-β in the subject with an amount of cholesterol or cholesterol derivative effective to inhibit activity of TGF-β thereby treating the condition. In a preferred embodiment, the cholesterol derivative is oxidized 7-DHC.03-05-2009
20110230454(AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH09-22-2011
20090203657Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof,08-13-2009
20080261932METHODS AND COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF AN EXACERBATION OF ASTHMA - The present invention relates to the use of a composition comprising: 10-23-2008
20080261933COMBINATION OF PROGESTERONE-RECEPTOR ANTAGONIST TOGETHER WITH A LUTEIN-HORMONE-RELEASING HORMONE AGONIST AND ANTAGONIST FOR USE IN BRCA MEDIATED DISEASES - The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists and antagonists, which can be combined together with the compound 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix and leuprolin.10-23-2008
20080261931Method and Means of Preventing and Treating Sleep Disordered Breathing - A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier.10-23-2008
20090203659METHOD OF ENHANCING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I08-13-2009
20090197845Method for treating olfactory disorder - Disclosed is a method for treating olfactory disorders, which comprises administering to a patient a therapeutically effective amount of 3-β-hydroxymethylglutarate CoA (HMG-CoA) reductase, which has excellent effects of protecting and regenerating olfactory nerve.08-06-2009
20120077787ORGANIC COMPOUNDS - New compounds of the Formula (I):03-29-2012
20090197844Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents - This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula08-06-2009
20090209503COLONIC DELIVERY THERAPEUTIC AGENTS FOR INFLAMMATORY BOWEL DISEASE - The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.08-20-2009
20090209502COMPOSITIONS OF GLYCOPYRRONIUM SALT FOR INHALATION - A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.08-20-2009
20090247494Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders - I have developed a unique pharmaceutical composition containing Omega-3 essential fatty acids and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as fissures and ulcers, hemorrhoids, pruritis ani, and colon-rectal disorders such as procto-sigmoiditis by topical application to or proximate the affected area.10-01-2009
20090253665METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR - Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine A10-08-2009
20120196839COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.08-02-2012
20120196838COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds according to Formula (I):08-02-2012
20090093447CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF - CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.04-09-2009
20090093446METHOD FOR ALLEVIATING KERATOCONJUNCTIVITIS SICCA - An improved method of increasing tear production is by intranasally administering a therapeutically effective amount of a capsaicinoid compound to patients with deficient tear production. Optional incorporation into the intranasal formulation of a topical corticosteroid or topical anesthetic compound is used to reduce transient nasal stinging and burning which may sometimes accompany intranasal administration of capsaicinoids.04-09-2009
20090258847Cholanic Acid Amides - 4-(3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid amides wherein the nitrogen of the amide group is substituted by a sulfonylaminocarbonyl-(C10-15-2009
20100273756ADJUNCTIVE FORMULATION AND METHODS FOR PALLIATION OF FINE WRINKLES, MOTTLED HYPERPIGMENTATION, TACTILE ROUGHNESS OF FACIAL SKIN AND RELATED DISORDERS - The present invention is generally directed to the treatment of fine wrinkles, hyperpigmentation, roughness of facial skin, improvement of photoaging, repair of sun damaged skin, and related disorders. In a formulation aspect, the present invention provides a formulation for the adjunct treatment of skin disorders, where the formulation includes tretinoin and azelaic acid. In a method aspect, the present invention provides a method for treating skin disorders. The skin disorders include fine wrinkles, freckles, solar lentigo, skin photodamage, aging process as reflected by changes in a patient's skin, Acne Vulgaris and Melasma or Post-inflammatory hyperpigmentation. The method includes the application of a formulation to a portion of the patient's skin, where the portion exhibits a skin disorder, and wherein the formulation includes tretinoin and azelaic acid.10-28-2010
20100160270USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.06-24-2010
20120142646Novel Compounds 621 - The present invention provides compounds of formula (I)06-07-2012
20100160271BICYCLIC MODULATORS OF H1 RECEPTORS - The present invention relates to new bicyclic modulators of H1 receptor activity, pharmaceutical compositions thereof, and methods of use thereof06-24-2010
20110130373METHODS FOR ADMINISTRATION AND FORMULATIONS FOR THE TREATMENT OF REGIONAL ADIPOSE TISSUE - Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.06-02-2011
20100261689PYRROLO [1,2-C] IMIDAZOLE DERIVATIVES FOR USE IN THE PROPHYLAXIS OR TREATMENT OF CANCER WHICH IS REFRACTORY TO KNOWN CANCER THERAPIES - The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent.10-14-2010
20090048220DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.02-19-2009
20100184734Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy - Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and/or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions associated with lipid metabolism, such as atherosclerosis, diabetes, metabolic disorders, etc. Compositions, dietary nutrients, food supplements and nutraceuticals comprising the herein described mixtures are also described.07-22-2010
20100273751SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - This invention relates to certain biologically active chemical compounds, namely benzoimidazolyl-pyrazine derivatives or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.10-28-2010
20100273749Method for Treating Dry-Eye Syndrome - The subject application provides an aqueous composition suitable for use as an artificial tear solution comprising one or more lipids produced by an enzyme of the diacylglycerol acyltransferase 2 (DGAT2) family and/or the acyl-CoA cholesterol acytransferase (ACAT) family. This invention also provides related methods.10-28-2010
20100261690NOVEL COMBINATIONS - The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a β10-14-2010
20100190759NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I:07-29-2010
20110059931BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - This invention provides compounds of formula I:03-10-2011
20110059930Composition for the Regulation of the Human Immune System and the Prevention and Treatment of Diseases Thereof - A nutritional supplement composed of phytosterols, anti-oxidants, and other complexes, including essential fatty acids, amino acids, peptides, proline rich polypeptides and digestive enzymes is described. The nutritional supplement may be used by individuals suffering from or at risk of developing immune system diseases; breast cancer, colon and prostate cancer; HIV infection; high cholesterol; or enlarged prostate. In the preferred form, the invention comprises phytosterols and antioxidants, together with essential fatty acids derived from amino acids, short chain peptides, proline rich polypeptides and digestive enzymes, and a microcellulose filler.03-10-2011
20130123222Synergistic Anti-Cancer Activity of SR16388 with Anti-Mitotic Drugs - The invention provides methods and compositions for inhibiting tumor growth in a mammal. The methods comprise administering to the mammal a synergistic combination of (E)-3-hydroxy-21-[2′-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene and a microtubulin inhibitor like paclitaxel or vincristine. The combination of the compounds more than additively inhibits growth of tumor cells.05-16-2013
20100216754COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.08-26-2010
20120142650METHOD FOR TREATING LUNG DISEASE - Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as β-lapachone. Methods of predicting whether a subject with a lung disease will respond to treatment with a naphthoquinone are also described herein.06-07-2012
20120142648METHODS FOR DELIVERING CLONIDINE COMPOSITIONS IN BIODEGRADABLE POLYMER CARRIER AND LOCAL STERIODS TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a steroid at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.06-07-2012
20100240628SKIN TREATMENTS - Compositions comprising an LXR activator and retinoic acid and/or a metabolic precursor thereto are useful in reducing the effects of chronoageing and/or photoageing of the skin.09-23-2010
20100216753CONTROLLED RELEASE OF DRUGS INTO/THROUGH THE SKIN - The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent.08-26-2010
20100240622NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating ophthalmic disorders; (b) treating cerebrovascular disorders; (c) treating cardiovascular disorders; (d) treating benign prostatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating sexual dysfunctions and (f) inducing abortions. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.09-23-2010
20100234333NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - A compound according to formula (I)09-16-2010
201002406238-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 - The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer.09-23-2010
20100240626ANTIEMETIC-ORAL CONTRACEPTIVE COMBINATION - The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic.09-23-2010
20100144686TOPICALLY APPLICABLE ANTI-INFLAMMATORY O/W EMULSIONS COMPRISING PRO-PENETRATING GLYCOLS - Stable, topically applicable, non-greasy and non-tacky oil-in-water (O/W) anti-inflammatory emulsions, useful, e.g., for the treatment of psoriasis, contain: 06-10-2010
20110237561ORGANIC COMPOUNDS - Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.09-29-2011
20100210610Organic compounds - There are provided according to the invention compounds of formula (I), in free or salt form, wherein R08-19-2010
20100222310BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS - The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal hyperplasia09-02-2010
20120142647Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases - The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.06-07-2012
20120142649COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE AND BUPIVACAINE TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release bupivacaine or lidocaine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer.06-07-2012
20100063017Ophthalmic Suspension for Ocular Use - A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries.03-11-2010
20100197645Thioamide Derivatives as Progesterone Receptor Modulators - Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.08-05-2010
20100197644Chemical Compounds 572 - Compounds of formula (I):08-05-2010
201202451316-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS - Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula09-27-2012
20090318396CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY - New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.12-24-2009
20090111785COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.04-30-2009
20090111784MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES - The present invention relates to novel uses of a steroid compound, which specifically binds to the androgen receptor (AR) but which is not metabolized by aromatase to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of hormone-dependent or hormone receptor regulated cancers in mammals.04-30-2009
20090111781Use of Cymipristone Type Compounds in Aids Treatment - This invention refers to use of cymipristone type compounds of formula (I), salt or solvate thereof in preparation of medicament for treating AIDS. Cymipristone type compounds are a new type glucocorticoid receptor antagonist. Pharmacological test shows that cymipristone has anti-glucocorticoid activity and very strong affinity with glucocorticoid receptor. Test indicates that cymipristone is a glucocorticoid antagonist on receptor level and can block the function of glucocorticoid receptor. The inventor uses cymipristone to test the inhibition on the growth of AIDS virus in vitro and finds that cymipristone has significant growth inhibition action on AIDS pathogen HIV-1.04-30-2009
201101182211,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE - The present invention relates to novel 1,4-diarylpyrimido[4,5-d]pyridazine-2,5-dione derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.05-19-2011
20130131027PARENTERAL PHARMACEUTICAL FORM WHICH RELEASES AROMATSE INHIBITOR AND GESTAGENS, FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention for the treatment of endometriosis relates to providing a parenteral dosage form (delivery system) for the controlled release of an aromatase inhibitor (AI) in a daily release rate that does not induce stimulation of the ovaries by negative feed-back of the pituitary-ovarian-axis (which would cause secretion of gonadotropins and stimulation of ovarian follicular growth) and a gestagen in a daily release rate below the ovulation inhibition dose that provides contraceptive efficacy based on local effects (e.g. reducing and thickening of the cervical mucus impairing sperm ascension, effects on the endometrium and on tubal motility impairing implantation and egg transport).05-23-2013
20130131028METHODS FOR TREATMENT OF SLEEP-RELATED BREATHING DISORDERS - Described herein are methods for modulation of the activity of the carotid body that afford therapeutic benefit for sleep-related breathing disorders and related conditions.05-23-2013
20130131029ANTISOLVENT SOLIDIFICATION PROCESS - The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid medium comprising at least one organic or inorganic compound which is to be solidified, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s).05-23-2013
20100311704PHARMACEUTICAL DELIVERY SYSTEMS FOR TREATMENT OF SUBSTANCE ABUSE AND OTHER ADDICTIONS - Disclosed are injectable pharmaceutical compositions that contain a therapeutically effective amount of an anti-addictive agent, an anti-inflammatory agent, and a pharmaceutically acceptable liquid carrier, methods of making the compositions, and uses thereof for treating addictions including substance abuse (or addiction to an abused substance) and addictive or compulsive behavior, by administering the composition to a subject in need thereof.12-09-2010
20100311703NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS - This compounds correspond to the formula (I), where: R12-09-2010
20130143848USE OF MEGESTROL ACETATE FOR IMPROVING HEART FUNCTION AND THE TREATMENT OF HEART INSUFFICIENCY - The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction.06-06-2013
20100324000DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS - The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the β2 adrenergic receptor.12-23-2010
20120135971ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS - The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.05-31-2012
20100331288CRYSTALLINE HYDRATE OF BETAMIMETIKA AND USE AS MEDICAMENT THEREOF - The present invention relates to a crystalline, enantiomerically pure hydrate of R-6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one-hydrochloride of formula (1) and its activity as a long-acting betamimetic, on its own or combined with one or more other active substances for treating respiratory complaints.12-30-2010
20100197642SLOW RELEASE MISOPROSTOL FOR OBSTETRIC AND/OR GYNAECOLOGICAL APPLICATIONS - Described are medical applications of Misoprostol defined by a particular combination of sustained release or slow release dosage form and oral administration route for obstetric and/or gynaecological conditions and treatments. Further described are combination medications of Mifepristone with the aforementioned Misoprostol dosage form and administration.08-05-2010
20110021476COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.01-27-2011
20110021474Ecdysterone Compounds - An ecdysterone compound is described. An ecdysterone compound may include ecdysterone and decanoic acid. An ecdysterone compound may further include ecdysterone and isobutyric acid. An ecdysterone compound may comprise a physiologically active salt or ester of ecdysterone. An ecdysterone compound may further comprise a physiologically active salt or ester of decanoic acid. Alternatively, an ecdysterone compound may include a physiologically active salt or ester of isobutyric acid.01-27-2011
20110245214ORGANIC COMPOUNDS - Optionally substituted 3-(thio, sulfonyl or sulfonyl)-7,8-dihydro-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or a substituted 3-(thio, sulfinyl or sulfonyl)-7,8,9-trihydro-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.10-06-2011
20110245213TREATMENT - The present invention concerns compositions that may be used in the prevention or treatment of medical conditions characterised by having an inflammatory component. The compositions comprise a therapeutically effective amount of an isothiocyanate (ITC). The composition may comprise further anti-inflammatory agents (e.g. plant-derived polyphenols).10-06-2011
20110130374Small Pyrimidine Derivatives and Methods of Use Thereof - Provided are pyrimidine derivatives which are ubiquitination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, and are useful for the treatment of cancer, angiogenesis disorders, and inflammatory disorders.06-02-2011
20090054382COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS - Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.02-26-2009
20090054381METHODS FOR TREATING RESPIRATORY DISORDERS - The invention provides methods for treating respiratory disorders in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one therapeutic agent. The hydralazine compound may be hydralazine hydrochloride. The respiratory disorders may be chronic obstructive pulmonary disease, pulmonary hypertension, emphysema, asthma, cystic fibrosis and bronchitis.02-26-2009
20110245212Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder - The present invention is a method of a non-continuous administration of a pharmaceutical to a female for a condition associated with the female's menstrual cycle, compromising in the administration of either 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid or RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. The active ingredients to be manufactured into a tablet or chewable formulation rich in cocoa flavonols such as dark chocolate no more than 65%. A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder compromising of administering to a female in need of treatment an effective amount of a compound. The first dose to be given at the onset of the premenstrual symptoms. This can be given two to four times a day up to seven days as directed. This is intended to be a short course of therapy to alleviate the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder.10-06-2011
20110118223NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in powder inhalant form, and methods of using it for treatment of respiratory disorders.05-19-2011
20100144687PHARMACEUTICAL COMPOSITIONS CONTAINING TESTOSTERONE AND AN AROMATASE INHIBITOR - A pharmaceutical dosage comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the dosage is an implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.06-10-2010
20110082126METHOD FOR TREATING INFLAMMATORY CONDITIONS - A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.04-07-2011
20090221539METHOD OF DETECTING AND REDUCING BOAR TAINT USING NUCLEAR RECEPTORS - A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole metabolism or androstenone in a pig, are disclosed These methods involve the use of the nuclear receptors constitutive androstane receptor, pregnane X receptor and farnesoid X receptor, which have been found to modulate the activity of the enzymes involved in skatole and/or androsterone metabolism09-03-2009
20100222308OPHTHALMIC, OTIC OR NASAL PHARMACEUTICAL COMPOSITION AND THE USE THEREOF - The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.09-02-2010
20100197643PHYTOCHEMICAL-RICH OILS AND METHODS RELATED THERETO - The invention relates to methods used in extracting oil from plants, plant fruits, and/or nuts, preferably fruits from plants of the family Arecaceae, or Palmae, even more preferably acai fruit. In some embodiments, the invention relates to methods of extracting the oil using an extraction solution comprising a volatile alcohol and volatile ketone. In other embodiments, the invention relates to oil from acai fruit and acai fruit by-products that contain enriched concentrations of phytochemicals.08-05-2010
20100016265Anti-inflammatory composition and method for preparation - A pharmaceutical anti-inflammatory preparation and method for preparation and treatment of arthritis and related inflammatory conditions used for mild to severe pain for relatively long acting results. This anti-inflammatory preparation comprises anti-inflammatory corticord steroid in aqueous-like suspension, a muscle relaxant in oil-like composition, and amide anesthetic compound in aqueous-like composition and Vitamin B-12 in aqueous-like composition. It is prepared by mixing the anti-inflammatory preparation at a rate and for a time sufficient to create a suspended emulsion. The anti-inflammatory preparation is administered while in suspended emulsion by intramuscular patient injection.01-21-2010
20090325912QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS - Compounds of formula I12-31-2009
20110178051TOPICAL SKIN CARE COMPOSITION - A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.07-21-2011
20100069340PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR - This invention is directed to a pharmaceutical composition comprising an Src kinase inhibitor and an aromatase inhibitor, and to the use of a combination of an Src kinase inhibitor and an aromatase inhibitor in treating abnormal cell proliferation and abnormal angiogenesis associated with cancer, including breast cancer.03-18-2010
20100063016Pharmaceutical Combinations - A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.03-11-2010
20100056486COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.03-04-2010
20090215735TOPICAL SOLUTION FORMULATIONS CONTAINING A CORTICOSTEROID AND A CYCLODEXTRIN - Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.08-27-2009
20090215732COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA - The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R08-27-2009
20090215734METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS - Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided.08-27-2009
20110178050USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM - There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol. Formula (I)07-21-2011
20100063015SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE - The present invention relates to a topical skin-care preparation in the form of an ointment containing mupirocin and betamethasone dipropionate as active principles and a carrier formulated with all or some of the following components: hydrogenated castor oil, polyethylene glycols and preservatives. The inventive preparation is advantageous over prior art compositions in that it has a specific therapeutic effect on primary and secondary skin infections, such as relief of pruritic inflammatory manifestations of dermatosis, a wide range of activity against the majority of bacterial species involved in skin infections, and a high level of activity against 03-11-2010
20110082125Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrocholoride and Dexamethasone Phosphate - Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.04-07-2011
20110251166DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR - The present invention provides a compound of formula (I) wherein: R10-13-2011
20110251165DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR - The present invention provides a compound of formula (I) wherein: R10-13-2011
20110251164Carboxamide Derivatives As Muscarinic Receptor Antagonists - The invention relates to compounds of formula10-13-2011
20110086826LIPOSOMAL CAMPTOTHECINS AND USES THEREOF - This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.04-14-2011
20100130457Phenothiazine Derivatives for Treatment of Asthma - The present invention relates to decreasing inflammation and airway obstruction in asthma. The invention also provides compositions and methods of reducing allergic reactions associated with asthma.05-27-2010
20110152226Development of New Selective Estrogen Receptor Modulators - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.06-23-2011
20110152227DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF - This invention relates to novel derivatives of tolterodine, 5-hydroxymethyl tolterodine, fesoterodine and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by muscarinic receptor antagonists.06-23-2011
20130165420SILICONE-BASED COMPOSITION FOR SKIN TREATMENT - The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.06-27-2013
20130165419COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS - Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.06-27-2013
20110160170COMPOSITIONS AND METHODS OF INDUCING ENDOPLASMIC RETICULUM STRESS RESPONSE - The present invention provides methods of inducing cell cycle arrest and/or cell growth inhibition, with the methods comprising administering to the cells an effective dose of the compounds of the present invention.06-30-2011
20100120732AGENT FOR PREVENTION AND/OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - Provided is an agent for prevention and/or treatment of systemic lupus erythematosus, which comprises, in combination, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazine-3-one or a solvate thereof and a corticosteroid. The pharmaceutical agent of the present invention is orally administrable, has fewer adverse effects, exhibits an excellent effect of suppressing the symptoms associated with SLE, and thus is useful for prevention and treatment of SLE.05-13-2010
20110212933Antiseptic Compositions for the Treatment of Infections - The invention provides antiseptic compositions that comprise a wide spectrum antiseptic component (WSAC) and optionally one or more other active ingredients. The WSAC comprises an alcohol, one or more antimicrobial phenol compounds, one or more antimicrobial agents, a solvent and optionally, one or more non-ionic detergents. Additional components such as additional active agents, and thickeners can also be optionally added. The antiseptic compositions have a wide-spectrum of antiseptic activity against microorganisms and exhibit minimal toxicity and minimal irritation and can be used to treat and/or prevent dermal, mucosal, cuticle (such as nail or hoof) or genital infections in a patient.09-01-2011
20110178049AVERMECTIN/HYDROCORTISONE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN. E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.07-21-2011
20090253662GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM - The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a −344 (T/T) polymorphism or a −344 (C/C) polymorphism in an aldosterone synthase CYP11B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.10-08-2009
20090075958CLOBETASOL PROPIONATE SHAMPOOS FOR THE TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP - Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith.03-19-2009
20110257139TREATMENT OF DIARRHOEA - A method for the treatment or prevention of diarrhoea (or diarrhoeal disease) in an individual comprises a step of administering a therapeutically effective amount of a potent and or selective FXR agonist to the individual. A method for the treatment or prevention of dysregulated fluid transport into the intestine in an individual is also described, and comprises a step of administering a therapeutically effective amount of a potent and or selective FXR agonist to the individual.10-20-2011
20110257136Ophthalmic Formulations Of Cetirizine And Methods Of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.10-20-2011
20100240627COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS - Methods of treating a glucocorticoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering, in combination, a glucocorticoid receptor agonist and a PPAR agonist in therapeutically effective amounts. It is an aspect of the present invention that the amount of the glucocorticoid receptor agonist used in a method of treating a glucocorticoid-responsive condition is less than an amount of the glucocorticoid receptor agonist necessary to achieve a therapeutic effect if administered in the absence of the PPAR agonist.09-23-2010
20080280862Methods, compositions, and kits for the treatment of pain - The invention features methods, compositions, and kits for the treatment of pain.11-13-2008
20110021479PYRROLOPYRIMIDINECARBOXAMIDES - The compounds of Formula (I),01-27-2011
20110021478COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.01-27-2011
20110021477COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.01-27-2011
20110021475Compositions And Methods for Treatment Of Fibrosis - Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided.01-27-2011
20110053901ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE - Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).03-03-2011
20110028441NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES - The invention relates to novel dihydrothienopyrimidines of the formula 1, and to pharmacologically acceptable salts thereof, formula (1) in which X is SO or SO02-03-2011
20100286103HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.11-11-2010
20110263552MODULATION OF SIDE EFFECT PROFILE OF 5-ALPHA REDUCTASE INHIBITOR THERAPY - Methods for modulating one or more side effects of 5-α-reductase inhibitor therapy are provided, where the method includes administering a 5-α-reductase inhibitor and testosterone undecanoate. Also provided are methods of maintaining or restoring a DHT serum level in an individual undergoing 5-α-reductase inhibitor therapy, where the method includes administering testosterone undecanoate in addition to 5-α-reductase inhibitor. Further provided are methods of treating or preventing a DHT-related condition, such as benign prostate hyperplasia (BPH) or prostate cancer by administering a 5-α-reductase inhibitor and testosterone undecanoate.10-27-2011
20110263548PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS - Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R10-27-2011
20110118224USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR - The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatase inhibitors useful for the preparation of a pharmaceutical formulation for the modulation, notably the inhibition of pre-term labor.05-19-2011
20110257138MONOTERPENES FOR TREATING RESPIRATORY TRACT DISEASES, IN PARTICULAR BRONCHOPULMONARY DISEASES - The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).10-20-2011
20110257137HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H10-20-2011
20100305081ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS - A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are compositions that further contain a cosmetic and/or pharmaceutical agent, along with the preparation and use thereof12-02-2010
20100184733SKIN TREATMENT COMPOSITION - The invention discloses skin treatment compositions consisting essentially of a mixture of ceramides, cholesterol, free fatty acids—the mixture being able to mimic skin identical lamellar structures—and nonionic emulsifiers. These compositions are liquid and pumpable at room temperature which means that they can be incorporated easily into cosmetic formulations with no need for heating. Furthermore, the skin treatment compositions allow the stable inclusion of long-chain ceramides into oil-in-water emulsions as well as into water-in-oil emulsions. Inclusion of short chain ceramides that can act as dermatological regulators did not affect the lamellar lipid organization. The skin treatment compositions are claimed as well as their use in cosmetic and dermatological formulations.07-22-2010
20100324001Novel Methods for the Treatment of Inflammatory Diseases - Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.12-23-2010
20100324002Inhaled combination therapy - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.12-23-2010
20100323997NOVEL USES - The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.12-23-2010
20120302533DERIVATIVES OF PYRIMIDO [6,1-A] ISOQUINOLIN-4-ONE - The present invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their application as inhibitors of phosphodiesterase (PDE) isoenzymes. More particularly the invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their use in medicine for example as bronchodilators with anti-inflammatory properties.11-29-2012
20120302532COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.11-29-2012
20120302531beta-2-Adrenoreceptor Agonists - Compounds of formula11-29-2012
20100168072Drug Combinations for the Treatment of Duchenne Muscular Dystrophy - Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.07-01-2010
20110136769METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR - A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.06-09-2011
20110136768IMATINIB MESYLATE FOR THE TREATMENT OF NEPHROGENIC SYSTEMIC FIBROSIS - Disclosed herein are methods of treatment and/or prevention of nephrogenic systemic fibrosis (NSF) in a subject in need thereof. The methods comprise administering an effective amount of imatinib mesylate to the subject, to thereby treat or prevent the nephrogenic systemic fibrosis. A corticosteroid and/or an antihistamine may also be administered. In one embodiment, the subject has chronic kidney disease, and/or is undergoing hemodialysis, and/or is in renal failure, and/or has been exposed to gadolinium such as gadolinium-containing contrast. The subject may also undergo an additional therapy to treat or prevent nephrogenic systemic fibrosis, chronic kidney disease, or renal failure, such as extracorporeal photopheresis, or administration of pentoxyphyline. Administration may be systemic, such as oral. Useful doses are from about 200 mg-600 mg, a day. Also disclosed are pharmaceutical compositions comprising imatinib mesylate and a pharmaceutically acceptable carrier, optionally formulated for oral administration.06-09-2011
20110118220Composition of bifonazole and its use - A medical composition includes Bifonazole and Triamcinolone acetonide acetate, and is mixed with pharmaceutical acceptable accessory. The medical composition of the present invention is used in treatment of skin superficial fungal infections, and also has the dual role of anti-inflammatory, anti-allergy and anti-itching functions.05-19-2011
20100216755ANTI-TUMOR AGENT - The present application provides a method for the treatment of tumors where the lethal dose of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is increased to twice or more, the toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, hepatic toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, and/or cardiovascular toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, by administering to a subject in need thereof a composition containing: 08-26-2010
20100069341TETRAHYDRO-PYRANOPYRAZOLE CANNABINOID MODULATORS - This invention is directed to a tetrahydro-pyranopyrazole cannabinoid modulator compound of formula (I):03-18-2010
20120309727COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a POE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.12-06-2012
20120309724NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula:12-06-2012
20120309725COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST - Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.12-06-2012
20120309723PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.12-06-2012
20090176751COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.07-09-2009
20100190758Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding - Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.07-29-2010
20110190247CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR - In its many embodiments, the present invention provides a novel class of cyclopropylchromene derivatives as modulators of a2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the a2C adrenergic receptors using such compounds or pharmaceutical compositions.08-04-2011
20110190246ESTRATRIENE DERIVATIVES COMPRISING HETEROCYCLIC BIOISOSTERES FOR THE PHENOLIC A-RING - The present invention is directed to novel pyrazolo-estrien and triazolo-estrien-derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by an estrogen receptor such as hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular diseases, hormone sensitive cancers and hyperplasia (in tissues including breast, endometrium, and cervix in women and prostate in men), endometriosis, uterine fibroids, osteoarthritis; and as contraceptive agents either alone or in combination with a progestogen or progestogen antagonist. The compounds of the invention are selective estrogen receptor modulators.08-04-2011
20110190245NANOSUSPENSION WITH ANTIFUNGAL MEDICATION TO BE ADMINISTERED VIA INHALATION WITH IMPROVED IMPURITY PROFILE AND SAFETY - The present invention is directed to new nanosuspensions of antifungal azole derivatives, particularly itraconazole, with with improved impurity profile optimized for inhaled administration for the prevention, reversal and medical treatment of fungal infections of the respiratory tract including adjacent lymph nodes. The new formulation which is devoid of particulate inorganic contamination can be safely administered by inhalation. This administration route results in an improved therapeutic effect and reduced side effect profile as compared to the previously used clinical administration route, i.e. oral or parenteral (intravenous) administration.08-04-2011
20110190244METHOD OF TREATMENT OF EGFR INHIBITOR TOXICITY - The invention provides a method of treating and/or preventing a toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy in a subject, the method comprising administering to the subject an effective amount of a steroid sulfatase (STS) inhibitor. The toxicity may be ocular toxicity; or dermatologic toxicity, such as papulopustular rash. The EGFR inhibitor may be selected from the group consisting of: a small molecule; an antibody or derivative or fragment thereof; another agent that targets the extracellular or intracellular domain of the EGFR, such as a tyrosine kinase inhibitor selected from the group consisting of: erlotinib; gefitinib; lapatinib; and any combination thereof. The EGFR inhibitor may also be antibody selected from the group consisting of: cetuximab; panitumumab; and any combination thereof.08-04-2011
20110263551METHOD FOR TREATING OTITIS EXTERNA - A method is provided for treating swimmer's ear and other types of otitis externa. The method comprises (a) diagnosing an instance of swimmer's ear in a patient; and (b) applying to the meatal tissues of the external ear of the patient, in a single application, a volume of a pharmaceutical composition preferably within the range of about 0.1 ml to about 1.5 ml. The pharmaceutical composition comprises a corticosteroid disposed in a viscous medium, and preferably also includes an antifungal agent. The corticosteroid is preferably betamethasone or a betamethasone derivative, and the concentration of the corticosteroid is preferably within the range of about 0.45 mg to about 0.9 mg per gram of the pharmaceutical composition.10-27-2011
20110201580PYRROLIDINE DERIVATIVES - The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.08-18-2011
201000224914-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY - The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R01-28-2010
20100022490Zilpaterol Enantiomer Compositions and Methods of Making and Using Such Compositions - This invention is directed generally to zilpaterol enantiomer compositions and, in particular, to compositions comprising the 6R,7R zilpaterol enantiomer. This invention is also directed to processes for making such compositions; methods for using such compositions to, for example, increase the rate of weight gain, improve feed efficiency, and/or increase carcass leanness in livestock, poultry, and/or fish; and uses of such compositions to make medicaments. This invention is further directed to methods for determining the absolute configurations of zilpaterol enantiomers.01-28-2010
20110218180Esters of Capsaicin for Treating Pain - The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia):09-08-2011
20110218179TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.09-08-2011
20100087409COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID - This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition.04-08-2010
20080242648COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER - The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.10-02-2008
20100069342FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.03-18-2010
20100035852COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE BOWEL - The present invention provides compositions and methods for treating inflammatory conditions (e.g., of the bowel). In particular, the present invention provides methods of treating (e.g., therapeutically and/or prophylactically treating) inflammatory conditions (e.g., of the bowel), compositions useful for such methods (e.g., antagonists and/or inhibitors of angiotensin II (AngII) receptor Type 102-11-2010
20110003780HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF - The present invention relates to the compound of the Formula I:01-06-2011
20110118222PSEUDOLIPID COMPLEX MIXTURE AND A SKIN EXTERNAL APPLICATION COMPOSITION CONTAINING SAME - Provided is a pseudolipid complex mixture comprising a pseudoceramide and a stearic acid and an external skin application composition comprising the same. The complex mixture has improved phase stability and a structure similar to that of the stratum corneum which can retain water and other beneficial materials, and accordingly the composition comprising the same can be used as an external skin application composition having improved moisturization and barrier repair capabilities.05-19-2011
20110059929SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 - In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.03-10-2011
20090088410METHODS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL)-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH OTHER THERAPIES - Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in combination with a second active agent. Particular second active agents are is prednisone, JAK1 inhibitor, JAK2 inhibitor, FLT3 inhibitor, BCL2 inhibitor, and HDAC inhibitor.04-02-2009
20090318397Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.12-24-2009
20080306037Product for Use in the Prevention and Treatment of Cardiovascular Diseases, Cancer and Chronic Inflammatory Diseases - The invention relates to a product that contains at least lycopene and oleic acid together with antioxidants of natural origin, such as β-carotenes, retinol, phytosterols, tyrosol and fatty acids, which is administered orally and which is specially indicated in the prevention of cardiovascular disease and in pathologies mediated by an anomalous activation of factor NF-κB, such as chronic inflammatory diseases and certain types of cancer, including colon cancer and prostate cancer.12-11-2008
20110092471USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS - The subject matter of this application relates to the combination of ciclesonide with an antihistamine.04-21-2011
20100125057TOPICAL SKIN CARE COMPOSITION - A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.05-20-2010
20090131381COMPOSITIONS COMPRISING HYDROQUINONE, FLUOCINOLONE ACETONIDE AND TRETINOIN FOR TREATING PHOTOAGING OF THE SKIN - Dermatological/medicament compositions containing a combination of hydroquinone, fluocinolone acetonide and tretinoin are useful for treating the signs of photoaging of the skin.05-21-2009
20100261688STABILIZATION OF OILY SUSPENSIONS COMPRISING HYDROPHOBIC SILICAS - The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions.10-14-2010
20090111783DERMATOLOGICAL COMPOSITIONS COMPRISING HYDROQUINONE, FLUOCINOLONE ACETONIDE AND TRETINOIN FOR TREATING THE HYPERPIGMENTATION OF PATHOLOGICAL SCARS - Dermatological medicament compositions contain a combination of hydroquinone, fluocinolone acetonide and tretinoin and are useful for the treatment of the hyperpigmentation of pathological scars, namely, hypertrophic scars and keloidal scars.04-30-2009
20090018108Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin - Hyperpigmentary skin disorders, notably those associated with psoriasis or eczema, are prevented/treated by administering to individuals in need of such treatment, thus effective amounts of medicaments containing a combination of fluocinolone acetonide, hydroquinone and tretinoin, formulated into a physiologically acceptable medium therefor.01-15-2009
201300124871-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.01-10-2013
20130012486COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY - The present invention provides compositions of an anti-inflammatory glucocorticosteroid and a glucocorticoid receptor (GR) modulator useful for inhibiting glucocorticoid receptor induced transactivation without substantially inhibiting glucocorticoid receptor induced transrepression. Also provided are methods of treating a disorder or condition and reducing the side effects of glucocorticosteroid treatment, using the compositions of the present invention.01-10-2013
201200409415-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES - The present invention provides a compound, which is a hydroxyquinolinone derivative of formula (I),02-16-2012
20100286102Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage - A cosmetic or pharmaceutical formulation that can be applied to the skin or hair is described, said formulation comprising: 11-11-2010
20110306581STABLE PERFLUOROCARBON EMULSION FOR USE AS AN ARTIFICIAL OXYGEN CARRIER - Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene oxide) block copolymer. These stabilized perfluorocarbon emulsions can be used in liquid and/or hydrogel phases of perfusion bioreactors or various other culture systems to enhance cell viability in thick tissue constructs, or as blood substitutes, although other applications may also be considered.12-15-2011
20110039812N-ALKYLCARBONYL-D-AMINO HYDROXYALKYL ESTER COMPOUNDS AND THEIR USE - The present invention pertains to certain N-alkylcarbonyl-D-amino acid hydroxylalkyl esters (NACHE), including, for example, (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid 3-hydroxy-propyl ester, and compositions comprising such compounds, that target sensory elements on nerve fibers and which are usefully administered to refresh and cool the skin and mucous membranes. This disclosure generally relates to menthol-like cooling compounds, which do not have the smell, taste, or short duration of action of menthol. These compounds are designed for delivery onto the surfaces of the oral cavity, upper respiratory tract and skin. These compositions produce refreshing and cooling sensations and are expected to inhibit the perception of cough stimuli, itch, pain, and discomfort from the body's surfaces. In the oral cavity these compositions produce refreshing cooling without adverse effects on taste. These compounds have special utility for mouth refreshment and for the treatment of respiratory disorders such as cough, asthma, and chronic obstructive pulmonary diseases. In addition, topical use inhibits perception of itch, irritation, pain and discomfort.02-17-2011
20120040940COMBINATION OF PILOCARPIN AND METHIMAZOL FOR TREATING CHARCOT-MARIETOOTH DISEASE AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.02-16-2012
20100273758Sulfonamide Derivatives For The Treatment Of Diseases - The invention relates to compounds of formula (1)10-28-2010
20110112058NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER - Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.05-12-2011
20090286762Pharmaceutical Formulations Comprising Azelastine and a Corticosteroid for the Treatment of Inflammatory or Allergic Conditions - The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of formula (II), (III), (IV)11-19-2009
20120040942NOVEL BRONCHODILATING DIAZAHETEROARYLS - The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.02-16-2012
20080287406Compositions and methods for treating medical conditions - The invention features methods, compositions, and kits for the treatment of pain, pruritus, immunoinflammatory disorders, musculoskeletal disorders, and the reduction of serum C reactive protein (CRP) in a patient having a disease or conditions associated with an increased CRP level. The methods, compositions, and kits of the invention provide for a combination therapy including an SSRI and a corticosteroid.11-20-2008
20100305080Novel Crystalline Salts of Montelukast - The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N′-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compositions comprising the salts and optionally other therapeutic agents.12-02-2010
20120040943COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.02-16-2012
2012014967017-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.06-14-2012
20110021473INHIBITORS OF PHOSPHODIESTERASE TYPE-IV - The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors.01-27-2011
20090325913Treatment of pain using satraplatin - The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the treatment of pain associated with metastatic hormone refractory prostate cancer.12-31-2009
20100179114S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents - The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.07-15-2010
20110028442DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR - The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the β2 adrenergic receptor.02-03-2011
20100323998TOPICAL COMPOSITION CONTAINING THE COMBINATION OF MUPIROCIN AND BECLOMETHASONE - The present invention relates to a topical pharmaceutical composition comprising mupirocin and beclomethasone, a process for its preparation, its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin and in the treatment of secondary bacterial infections in patients of steroid responsive dermatoses.12-23-2010
20120065173CHEMICAL COMPOUNDS - Compounds of formula (I):03-15-2012
20120157420TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM - A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral (including transdermal, intravenous, subcutaneous, intramuscular) routes. Inflammatory and immunological processes have been shown to cause secondary damage to CNS tissues in individuals with acute CNS injury. The present invention administers one or more of the following medications, which have properties that mitigate the inflammatory and immunological processes that lead to secondary CNS damage, via trans-dermal absorption: a statin compound (e.g., a HMG-CoA reductase inhibitor), a progesterone compound, or a cholinesterase inhibiting compound, among others, either alone or in combination with other compounds.06-21-2012
201202527692-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS - The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:10-04-2012
20080242647Use of Molt-Accelerating Compounds, Ecdysteroids, Analogs Thereof, and Chitin Synthesis Inhibitors for Controlling Termites - The subject invention relates in part to the oral administration of ecdysteroids for controlling subterranean termites. Preferred ecdysteroids for use according to the subject invention are ecdysone, certain ecdysone analogs, and 20-hydroxyecdysone, for example. In some preferred embodiments, one or more of these compounds is used in a termite bait in combination with one or more chitin synthesis inhibitors (CSI), such as hexaflumuron and/or noviflumuron. The subject invention also relates to mixtures comprising these two active ingredients. The ecdysteroid analog or molt-accelerating compound (MAC) typically induces a preliminary molting event in termite workers, which then allows the CSI to further disrupt the molt and cause mortality. The combination of these active ingredients, causing accelerated molting together with inhibition of chitin synthesis, is surprisingly shown herein to enhance activity against termites, as compared to either group of compounds alone.10-02-2008
20100152145USE OF 3-ALPHA-ANDROSTANEDIOL, OPTIONALLY IN COMBINATION WITH A PDE5 INHIBITOR, IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5 phosphodiesterase (PDE5) inhibitor.06-17-2010
20120046259COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID - This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition.02-23-2012
20120046257Methods for Administration and Formulations for the Treatment of Regional Adipose Tissue - Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.02-23-2012
20120046256Lipolytic Methods for Regional Adiposity Comprising Salmeterol or Formoterol - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.02-23-2012
20120046255NON-STEROIDAL COMPOUNDS - The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is02-23-2012
20120004203TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD - The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.01-05-2012
20120004202MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula01-05-2012
20090131380Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof - The present invention provides the combination of topical 3,3,′5,5′-tetraiodothyroacetic acid and betamethasone for the treatment of skin psoriasis results in a better outcome than the combination of topical calcipotriol and betamethasone. The present invention also provide a method for treatment of skin psoriasis by using the composition of 3,3,′5,5′-tetraiodothyroacetic acid and betamethasone.05-21-2009
20100144685INHIBITING CYCLIN D POLYPEPTIDES - This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.06-10-2010
20120010179Methods of using a thiazole derivative - This invention relates to a method of treating a disease, disorder, or condition in a patient comprising administering to a patient a therapeutically effective amount of a thiazole derivative, tetomilast. The invention further relates to the administration of at least one beta2-adrenergic receptor agonist, with tetomilast for treating a disease, disorder, or condition. The invention further relates to the administration of an anti-inflammatory steroid, with tetomilast and at least one beta2-adrenergic receptor agonist for treating a disease, disorder, or condition.01-12-2012
20100273753ORGANIC COMPOUNDS - 1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1H, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction.10-28-2010
20090111782COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS - Methods of treating a glucocorticoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering, in combination, a glucocorticoid receptor agonist and a PPAR agonist in therapeutically effective amounts. It is an aspect of the present invention that the amount of the glucocorticoid receptor agonist used in a method of treating a glucocorticoid-responsive condition is less than an amount of the glucocorticoid receptor agonist necessary to achieve a therapeutic effect if administered in the absence of the PPAR agonist.04-30-2009
20110092469Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy - The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.04-21-2011
20110166114METHOD FOR TREATING SNORING AND SLEEP APNEA WITH LEUKOTRIENE ANTAGONISTS - A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.07-07-2011
20110166113METHOD FOR TREATING THE HYPERPIGMENTATION OF PATHOLOGICAL SCARS - Dermatological medicament compositions contain a combination of hydroquinone, fluocinolone acetonide and tretinoin and are useful for the treatment of the hyperpigmentation of pathological scars, namely, hypertrophic scars and keloidal scars.07-07-2011
20110166112METHOD FOR STIMULATING PLATELET PRODUCTION - Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.07-07-2011
20120015923USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS - We describe for the first time that andrographolide derivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-?B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.01-19-2012
20120015922USE OF ARTEMISININ DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - Artesunate is a derivative of artemisinin isolated from a Chinese herb 01-19-2012
20120015920HETEROBICYCLIC METALLOPROTEASE INHIBITORS - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.01-19-2012
20120015919THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS - Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.01-19-2012
20120115828MEDICINAL CREAM CONTAINING MICONAZOLE NITRATE, HYDROCORTISONE ACETATE, AND A BIOPOLYMER, AND A PROCESS TO MAKE IT - The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections & skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) a combination of active pharmaceutical ingredients (APIs), miconazole and hydrocortisone acetate used in treating bacterial skin infections & skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, corticosteroid in the form of hydrocortisone acetate, and an antibacterial agent in the form of miconazole, are incorporated in cream base for use in treating bacterial skin infections and skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.05-10-2012
201201158273-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS - The present invention relates to a novel 3-aminobenzamide, compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R05-10-2012
20120115825CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF - The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I)05-10-2012
20120022031COMPOSITION AND METHODS OF TREATMENT OF BACTERIAL MENINGITIS - A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.01-26-2012
20120022030Tetracyclic Lactame Derivatives - The present invention describes tetracyclic compounds of formula (IA) or (IB),01-26-2012
20120058980AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS - The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1,03-08-2012
20120058979METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS - The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.03-08-2012
20120058978METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.03-08-2012
20100022492THERAPEUTIC CAUSING CONTRACTION OF MUCOSAL TISSUE, METHOD OF TREATING DISEASES RELATING TO MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC SET - The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method. The invention also encompasses a therapeutic causing contraction of nasal mucosal tissue containing ethanol as the active ingredient preferably together with a steroid and/or an antihistaminic agent; a method of treating diseases with mucosal inflammation using the above therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method.01-28-2010
20120270849COMBINATIONS OF NIACIN, OMEGA-3 AND PLANT STEROLS/STANOLS FOR PREVENTION CHOLESTEROL TREATMENT - Provided herein are nutritional compositions, regimens and methods for the prevention, mitigation, and treatment of a cholesterol abnormality. In some embodiments, the invention comprises combinations of niacin (precursor), and at least one ingredient selected from the group consisting of: an Omega-3 fatty acid, Omega-3 fatty acid precursor, or Omega-3 fatty acid derivative, and: a plant sterol, a plant sterol precursor, or a plant sterol derivative. In other embodiments, the combination includes all three of those ingredients.10-25-2012
20120270848Novel Compositions and Therapeutic Methods Using Same - The present invention includes compositions and methods for treating a subject in need of opioid therapy, wherein the opioid therapy produces or has the possibility of producing respiratory depression or a breathing control disorder in the subject.10-25-2012
20120065176TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE - It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized by impaired insulin-dependent signaling by targeting components of the defective insulin signaling pathway. The disease or condition may be treated by administering a therapeutic agent that activates the insulin signaling pathway, in particular, therapeutic agents that act post-insulin receptor to modulate intracellular effector molecules. An exemplary modulator is metformin. Metformin may be administered alone or may be co-administered with another therapeutic agent for treating the muscle disease or condition, such as a corticosteroid.03-15-2012
20120065175METHOD OF PREPARING DRY POWDER INHALATION COMPOSITIONS - The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.03-15-2012
20120108557FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.05-03-2012
20100222309SKIN PROPERTY-IMPROVING THERAPEUTIC AGENT COMPRISING A MORPHINAN DERIVATIVE OR ANY OF ITS PHARMACOLOGICALLY PERMISSIBLE ACID ADDITION SALTS AS AN ACTIVE INGREDIENT - A skin property-improving therapeutic agent includes a compound having a specific morphinan skeleton typified by a compound 1 represented by the following formula (II) or any of its pharmacologically permissible acid addition salts as an active ingredient:09-02-2010
20120071450ORGANIC COMPOUNDS - Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.03-22-2012
20120071451METHOD OF TREATING NONALCOHOLIC STEATOHEPATITIS WITH ELEVATED DOSES OF URSODEOXYCHOLIC ACID - The present invention is directed to a method for the treatment of nonalcoholic steatohepatitis (NASH) by administering an elevated dose of ursodeoxycholic acid (UDCA), or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment, wherein the patients demonstrate a significantly improved glycemic profile during treatment.03-22-2012
20120157419METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE - The present invention relates to methods for treatment, prevention, and inhibition of progression of Alzheimer's disease, and other brain diseases characterized by amyloid plaque deposits, comprising the administration to a subject a bile acid fatty acid conjugates or bile salt fatty acid conjugate (FABAC).06-21-2012
20110092470METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION - A method of treating male sexual dysfunction or erectile dysfunction by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.04-21-2011
20090197843Treatment of Prevention of Unscheduled Bleeding in Women on Progestogen Containing Medication - The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; renin inhibitors and combinations thereof. Other aspects of the invention relate to a pharmaceutical composition containing a RAS suppressor and a progestogen and to a pharmaceutical kit having a plurality of dosage units, wherein at least one dosage unit contains a progestogen; at least one dosage unit contains an estrogen; and at least one dosage unit contains a RAS suppressor.08-06-2009
20100331289Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.12-30-2010
20110105448Stable Topical Formulation Comprising Voriconazole - The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a process for preparing the same and use of such formulation for the treatment of local or non-systemic fungal infections in a subject. In particular, the present invention relates to a stable topical formulation exhibiting a storage stability at a temperature of about 40° C. and a relative humidity of about 75% for a period of at least 3 months, and contains not more than 9% w/w total impurities (based on total weight of the formulation) formed upon storage.05-05-2011
20110105447NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL - Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.05-05-2011
20110105446Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.05-05-2011
20100093682LIPID COMPOSITION HAVING EXCELLENT SHAPE RETENTION PROPERTY AND PRODUCT - It is to provide a technique for preventing aggregation or caking of menthol at the time of its keeping. In addition, it is to provide a lipid composition, which can show excellent thermal stability even in the case of high temperature at the time of keeping menthol and at the time of blending in a product, does not cause mutual aggregation of powders, particles, flakes, pellets, sticks and the like of menthol, and can maintain its shape retention property. From 10 to 50% by mass of sterols are added to and mixed with from 50 to 90% by mass of menthol, and the resultant is melted with heating. Paraffins may be further added and mixed in an amount of 20% by mass or less, based on the lipid composition.04-15-2010
20100093681NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR - The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.04-15-2010
20100093680USE OF 3-ALPHA-ANDROSTANEDIOL, OPTIONALLY IN COMBINATION WITH A 5-HT1A AGONIST, IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a 5-HT1A agonist. Optionally, said 3-alpha-androstanediol and said 5HT104-15-2010
20120316143Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range.12-13-2012
20120316142QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS - Compounds of formula I12-13-2012
20120316144ANTIFUNGAL AGENT - An antifungal agent including a mastic normal-hexane extract containing at least one of triterpenes expressed by the following chemical formulas 1 to 6;12-13-2012
20120122826NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in combination with a steroid, and methods of using it for treatment of respiratory disorders.05-17-2012
20120122825USE OF PICOPLATIN TO TREAT PROSTATE CANCER - The invention provides a method of treatment of metastatic hormone-refractory prostate cancer involving substantially as concurrent administration of picoplatin and docetaxel. Prednisone may also be administered. Dosages and dosing regimens are provided.05-17-2012
20090131382TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB - 4-(4-methylpiperazin-1-ylmethyl)-N—[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I05-21-2009
20110183948TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS - Provided is a method of treating a fibrotic condition with a hedgehog inhibitor.07-28-2011
20120214774TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.08-23-2012
20120214775Pharmaceutical Salts of 3-O-(3',3'-Dimethylsuccinyl) Betulinic Acid - Salts of 3-O-(3′,3′-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of DSB and the pharmaceutical compositions are also provided.08-23-2012
20120129821INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.05-24-2012
20120129820NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS - The present invention provides pharmaceutical compositions comprising one or more CRTH2 antagonists 1 and one or more further active compounds 2.05-24-2012
20130172301BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - This invention provides compounds of formula I:07-04-2013
20130172304Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders - The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient selected from the group consisting of compounds used for female hormone replacement therapy 2a, compounds used for menopause problems 2b, and contraceptives 2c.07-04-2013
20120252770Chemical Compounds 572 - Compounds of formula (I):10-04-2012
2009004284417ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS - Compounds having the structure, their salts or N-oxide derivatives:02-12-2009
20120172343PHARMACEUTICAL COMPOSITION FOR EMERGENCY CONTRACEPTION - The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.07-05-2012
20080300226Combination of Anticholinergics and Glucocorticoids for the Long-Term Treatment of Asthma and COPD - The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.12-04-2008
20100048520RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION - The present invention relates to compositions and methods for treating rectal disorders.02-25-2010
20100048522Method Of Treating Otic Infections With Moxifloxacin Compositions - Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.02-25-2010
20100048521COMBINATION OF A GLUCO-KORTICOID AND BETA-CYCLODEXTRIN CONJUGATED VITAMIN A-DERIVATE COMPLEX - The present invention is related to a pharmaceutical combination of a glucocorticoid and a β-cyclodextrin conjugated vitamin A derivative complex as well as a pharmaceutical composition comprising the same. The combination and the composition of the invention can be used for reducing or eliminating skin atrophy induced by treatment with glucocorticoids (GC). Also comprised is a method for reducing or eliminating skin atrophy induced by GC treatment. Furthermore the invention concerns a kit comprising a glucocorticoid and a β-cyclodextrin conjugated vitamin A derivative complex.02-25-2010
20100273754ORGANIC COMPOUNDS - 1- or 2-substituted (6aR,9aS)-3-(phenylamino)-5-6a,7,8,9,9a-hexahydro-5-methyl-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(1H or, 2H)-one compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.10-28-2010
20100273757PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS - The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R10-28-2010
20100273755DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - This invention relates to a compound of formula I:10-28-2010
20100273752MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS - The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent or treat pathologies involving histamine H4 receptor.10-28-2010
20100273750SEROTONIN RECEPTOR ANTAGONISTS FOR TREATING ARTHRITIS - The present invention relates to serotonin receptor antagonists for treating inflammatory arthritis and related conditions. The present invention also relates to a kit comprising a pharmaceutical composition comprising a serotonin receptor antagonist and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions. In addition, the present invention relates to a method of treating inflammatory arthritis and related conditions comprising administration of a serotonin receptor antagonist. The method is preferably carried out on a subject in need of treatment. The inflammatory arthritis is preferably rheumatoid arthritis.10-28-2010
20090088408PHARMACEUTICAL COMPOSITIONS ON ANTICHOLINERGICS, CORTICOSTEROIDS AND BETAMIMETICS - The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases.04-02-2009
20100009950SUBSTITUTED ETHANOLAMINES - The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.01-14-2010
20100292196PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided.11-18-2010
20120220558Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives - The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is:08-30-2012
20120220557LIQUID PROPELLANT-FREE FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG - Liquid, propellant-free pharmaceutical formulation for administration by nebulization which comprising an antimuscarinic drug as active ingredient are useful for the prevention and/or treatment of a wide range of conditions including respiratory disorders.08-30-2012
20090325915Crystalline Levosalbutamol Sulphate and Polymorphic Forms Thereof - The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III.12-31-2009
20120190658Method And Composition For The Treatment Of Adverse Skin Conditions - A multi-component medicament composition for the treatment of adverse skin conditions such as eczema or psoriasis comprises a combination of a steroid and silicone.07-26-2012
20120190657BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - This invention provides compounds of formula I:07-26-2012
20120258940METHOD FOR TREATING HAEMATOLOGICAL CANCERS - The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.10-11-2012
20120258939PHARMACEUTICAL MANUFACTURING PROCESS - The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.10-11-2012
20110124617Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent - This invention relates to combination therapies for the treatment of breast cancer comprising administering to a subject in need thereof a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist, or an estrogen receptor downregulator) and to compositions (e.g., pharmaceutical compositions) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent. This invention also relates to a method of treating the side effects (e.g., vasomotor disturbances, osteoporosis and musculoskeletal complaints) associated with anti-estrogen therapy in a subject treated with one or more anti-estrogenic agents (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist or an estrogen receptor downregulator). The method comprises administering to the subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.05-26-2011
20110124616METHOD FOR TREATING RETINAL CONDITIONS USING AN INTRAOCULAR TAMPONADE - A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.05-26-2011
20110124615USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA - According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris.05-26-2011
20110124614Methods And Compositions For The Treatment of Autoimmune Disorders - Methods and compositions are provided which confer protection against autoimmune diseases without triggering intracellular estrogen receptors. Such methods and compositions limit the side effects of steroids while providing the benefits conferred by such medications through the activation of membrane estrogen receptors.05-26-2011
20110124613Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma - The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a β05-26-2011
20120232043LUBIPROSTONE FOR OBSTETRICAL OR GYNECOLOGICAL APPLICATIONS - The invention relates to a method for terminating pregnancy or for menstrual induction, which method comprises administering a female subject with lubiprostone, preferably in combination of a progesterone receptor antagonist, such as mifepristone.09-13-2012
20100204190NEW COMBINATIONS - The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.08-12-2010
20120264722PHARMACEUTICAL FORMULATIONS AND USES THEREOF IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION - The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.10-18-2012
20110003781Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof - Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.01-06-2011
20110046096NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES - The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO02-24-2011
20120322778PHARMACEUTICAL COMPOSITIONS - Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.12-20-2012
20090298802Pharmaceutical Compositions - Disclosed are inhalable medicaments and methods based on an anticholinergic in combination with a corticosteroid, and a long acting beta agonist, for simultaneous or sequential administration in the prevention or treatment of a respiratory, inflammatory or obstructive airway disease. In addition, disclosed are inhalable medicaments and methods based on combinations of an anticholinergic and a corticosteroid; an anticholinergic and a long acting beta agonist; or a corticosteroid and a long acting beta agonist, for simultaneous or sequential administration in the prevention or treatment of a respiratory, inflammatory or obstructive airway disease. Also disclosed are inhalable medicaments and methods comprising a phosphodiesterase IV inhibitor for administration in the prevention or treatment of a respiratory, inflammatory or obstructive airway disease.12-03-2009
20110224176Lyophilized Cake Formulations - Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection.09-15-2011
20100234332NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl. 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R09-16-2010
20120277200USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.11-01-2012
20120277199Modulation of Gel Temperature of Poloxamer-Containing Formulations - Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).11-01-2012
20110263547C-19 STEROIDS FOR SPECIFIC THERAPEUTIC USES - The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR10-27-2011
20110269726Method of and system for treatment of inflammatory skin conditions - For treating inflammatory skin conditions a treatment cream including hydrocortisone is applied on a skin; and the applying the treatment cream is combined with treatment of the skin with moisturizer with a moisturizer.11-03-2011
20120088744COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.04-12-2012
20120088743COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniablcyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.04-12-2012
2011029476616 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use - The present invention provides compounds of formula (I) wherein R12-01-2011
20110319371PHARMACEUTICAL FORMULATIONS COMPRISING 4-HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL - Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.12-29-2011
20120101076CARBONATE DERIVATIVES FOR THE TREATMENT OF COUGH - The invention relates to use of certain quinuclidine carbonate derivatives as cough suppressants, particularly for treating patients with upper respiratory tract infections or asthma.04-26-2012
20120101074METHOD AND MEDICATION FOR PREVENTION AND TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA - An effective dose of a pharmaceutically acceptable phenylbutyrate salt such as sodium phenylbutyrate applied to human ocular tissues or through injection or other means prevents ocular hypertension and treats glaucoma in humans, leading to a new medical therapy for lowering the intraocular pressure via a mechanism different from the existing glaucoma medications. This compound can be formulated in combination with topical or other forms of steroids in prevention and treatment of steroid induced ocular hypertension and glaucoma.04-26-2012
20130012485ORGANIC COMPOUNDS - Compounds of the formula (I) are provided:01-10-2013
20100173881COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention features methods and compositions for the treatment of immunonflammatory disorders.07-08-2010
20100173880ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.07-08-2010
20100173879USE OF A COMPOUND ANTAGONIST TO THE NK2 RECEPTORS OF NEUROKININ A FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING OF SEXUAL DYSFUNCTION - The invention relates to the use of a compound antagonist to the NK07-08-2010
20100173878ORGANIC COMPOUNDS - 2-benzyl-3-(optionally hetero)arylamino-[2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-diones, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors.07-08-2010
20130018023COMPOSITIONS FOR TOPICAL ADMINISTRATION - The invention provides a composition comprising benzoyl peroxide or derivative thereof; and at least one antibiotic compound selected from pseudomonic acid, retapamulin, fusidic acid and derivatives thereof; methods and uses of a composition of the invention in the treatment of at least one topical disease or disorder and kits comprising a composition of the invention.01-17-2013
20110160172FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.06-30-2011
20110160171TREATMENT OF CONGESTION USING STEROIDS AND ADRENERGICS - A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg.06-30-2011
20130023503NK1 ANTAGONISTS01-24-2013
20130023502SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS - The invention relates to new substituted pyridinyl-pyrimidines of formula 01-24-2013
20130172303ROFLUMILAST COMPOSITIONS FOR THE TREATMENT OF COPD - The present invention relates to pharmaceutical compositions comprising roflumilast in combination with a corticosteroid and/or a leukotriene receptor antagonist. The invention also relates to the use of such compositions for the treatment of Chronic Obstructive Pulmonary Disorder (COPD).07-04-2013
20090018109COMBINATIONS OF STEROIDS AND METHYLXANTHINE COMPOUNDS - There is provided a medicament comprising a combination of a methylxanthine compound of formula I and a steroid of formula II and their use as pharmaceuticals, in particular for the treatment of inflammatory or obstructive airways diseases.01-15-2009
20080227762LUPEOL ANTI-TUMOR AGENT AND USES THEREOF - The present invention provides a method of treating melanoma comprising parenterally administering to a human a therapeutically effective amount of a parenteral composition of a Lupeol-derived anti-tumor compound.09-18-2008
20080227761METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.09-18-2008
20130178453Cannabinoid Agonists - The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I).07-11-2013
20130178454COMBINATION OF TESTOSTERONE AND ORNITHINE DECARBOXYLASE (ODC) INHIBITORS - The present invention is generally directed to a method of increasing testosterone levels in a subject comprising; administration of testosterone or analogue thereof along with an ornithine decarboxylase (ODC) inhibitor. The method selectively promotes beneficial effects of testosterone, while preventing side effects associated with testosterone administration. The present invention also directed to pharmaceutical composition and kits comprising testosterone or analogue thereof; ornithine decarboxylase inhibitors. The composition selectively promotes beneficial effects of testosterone, while preventing side effects of testosterone administration. In some embodiments, the present invention relates to a method of treatment of low testosterone levels in a subject by administrating testosterone and ODC inhibitor while preventing side effects associated with testosterone administration. The method and composition of the invention particularly prevents potential adverse effects on the prostate in men and virilization in women.07-11-2013
20110269728METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER - Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.11-03-2011
20110269727COMPOSITION TO REDUCE ALLODYNIC BACK PAIN AND RELATED METHOD OF USE - The invention relates to a pharmaceutical composition to reduce back pain comprising two compounds: an opioid antagonist and a direct-acting alpha 2 adrenegic agonist. The Opioid antagonist is selected from the group consisting of alvimopan, nalmefene, naloxone, naltrexone, methylnaltrexone, nalorphine, and pharmaceutically acceptable salt. The direct-acting alpha 2 adrenegic agonist is selected from a group consisting of Apraclonidine, Brimonidine, Clonidine, Detomidine, Dexmedetomidine, Guanabenz, Guanfacine, Lofexidine, Medetomidine, Romifidine, Tizanidine, Tolonidine, Xylazine and Fadolmidine. In one embodiment, the composition may include naltrexone (or its pharmaceutically acceptable salt) as the opioid antagonist and clonidine hydrochloride (or its pharmaceutically acceptable salt) as the direct-acting alpha 2 adrenegic agonist. It is preferred naltrexone be administered with a second agent such as an antitussive, expectorant, decongestant, or antihistamine. The dosage of naltrexone may range between 0.25 mg to 15 mg, while the dosage of clonidine hydrochloride ranges between 0.0125 mg and 0.3 mg.11-03-2011
20130172302QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF - Compounds of formula (I):07-04-2013
20130096095SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR - The present invention provides tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof. The present invention provides a method of using tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof.04-18-2013
20130116221THEOBROMINE FOR INCREASING HDL-CHOLESTEROL - Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine.05-09-2013
20130116219ANTIMICROBIAL CARBOLINE COMPOUNDS - The invention provides compositions comprising carboline compounds for treating infections such as viral conjunctivitis. The invention also provides methods for treating of other infections, including ocular infections. More particularly, the present invention relates to compositions comprising carboline compounds for the treatment of ocular infections such as viral conjunctivitis, particularly those caused by adenovirus05-09-2013
20130116218METHODS AND COMPOSITIONS OF BILE ACIDS - Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system.05-09-2013
20130116220Polymeric Pheromone Formulation and Method of Use to Calm Stress-Related Behavior in Mammals over an Extended Period of Time - Pheromone compositions comprising a combination of squalene, linoleic acid and 1-docosanol are described, along with methods of using the pheromone compositions to modify behavior in mammals. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors.05-09-2013
20130102576DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Compounds, pyridine N-oxides, and pharmaceutically acceptable salts of formula (I) are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and for preventing and/or treating diseases of the respiratory tract characterized by airway obstruction, such as asthma or COPD.04-25-2013
20130102575PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.04-25-2013
20130210785PROGESTERONE ANALOGS AND USES RELATED THERETO - This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.08-15-2013
20130123221COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES - Provided herein are compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are pharmaceutical compositions comprising a non-homogenous vehicle, an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent. Additionally, methods are described for the use of said pharmaceutical compositions for the treatment of skin diseases and disorders, and devices are described for the preparation of said pharmaceutical compositions.05-16-2013
20130131026COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS OF INFLAMMATORY RELATED CONDITIONS USING A COMBINATION OF AN ANTIHISTAMINE AND A STIMULANT - The present invention relates to compositions containing stimulant and anti-histamine compounds, to methods for treating symptoms related to inflammation using the combination compounds, and to a method for preparing the compositions.05-23-2013
20130157990METHOD OF DRUG DETOXIFICATION - A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state.06-20-2013
20110212932AQUEOUS CLEAR SOLUTIONS OF FLUOCINOLONE ACETONIDE FOR TREATMENT OF OTIC INFLAMMATION - A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.09-01-2011
20110224179MEDICAMENT AND METHOD OF DIAGNOSIS - We disclose a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonise the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma.09-15-2011
20110224177COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - A combination which comprises (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.09-15-2011
20110275603NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS - The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.11-10-2011
20110275602PHARMACEUTICAL ASSOCIATION, COMPOSITIONS FOR TOPICAL USE, FORMS OF DOSAGE AND METHOD OF TREATMENT OF ACUTE OR CHRONIC OTITIS IN PET ANIMALS - The present invention refers to a new pharmaceutical association comprising antibiotic from the class of quinolones, azole antifungus, corticoid anti-inflammatory and local anesthesic from the class of amines. The pharmaceutical association of the present invention is particularly appropriate for the treatment of acute or chronic otitis in pet animals, caused by both bacteriae and fungi. The present invention also refers to compositions for topical use, as well as dosage forms comprising said pharmaceutical association, which are particularly appropriate for the treatment of acute or chronic otitis in cats and dogs.11-10-2011
20110237560MODULATING AND/OR DETECTING ACTIVATION INDUCED DEAMINASE AND METHODS OF USE THEREOF - A method for stratifying a subject, said method comprising: measuring the AID expression and/or activity in a first sample of the subject, and comparing said expression and/or activity to a reference AID expression and/or activity, wherein an AID expression and/or activity in the first sample of the subject that is higher than the reference AID expression and/or activity is indicative that the subject would benefit from a treatment with at least one Heat Shock Protein 90 (Hsp90) inhibitor.09-29-2011
201102375596-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 - In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.09-29-2011
20130150335PACLITAXEL/STEROIDAL COMPLEX - A paclitaxel/steroid complex comprising paclitaxel and steroid is disclosed. The molar ratio of paclitaxel to steroid is 1:0.2˜4, preferably 1:0.25˜2. A process for the preparation thereof and the use thereof in the manufacture of submicron emulsion, dry emulsion, self-microemulsifying system are also disclosed.06-13-2013
20130137666COMBINATIONS OF NIACIN COMPOUNDS, OMEGA-3 FATTY ACID COMPOUNDS, AND PHYTOSTEROL COMPOUNDS FOR PREVENTION AND/OR MITIGATION OF ERECTILE DYSFUNCTION - Provided herein are nutritional compositions, regimens and methods for the prevention, mitigation, or treatment of ED. In some embodiments, the invention comprises compositions of at least two (and preferably three) members selected from the group consisting of a niacin compound, an Omega-3 fatty acid compound, and a phytosterol compound.05-30-2013
20130137665DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - This invention relates to a compound of formula I:05-30-2013
20100317636REDUCING THE RISK OF CHRONIC LUNG DISEASE IN INFANTS - Described herein is a method for reducing the risk of chronic lung disease in an infant suffering from respiratory distress syndrome by administering to the infant a combination of a corticosteroid having a high local to systemic anti-inflammatory activity (e.g., budesonide) and a lung surfactant.12-16-2010
20100317635TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS - Novel methods for reduction or elimination the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes type 2, loss of muscle mass, adiposity, Alzheimer's disease, loss of cognition, loss of memory, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and an antiestrogen or a selective estrogen receptor modulator, particularly compounds having the general structure:12-16-2010
20100317634PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS - One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R12-16-2010
20110312925METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES - Methods for treating or reducing the likelihood of acquiring estrogen-related (e.g. estrogen-exacerbated) diseases including endometriosis include administering to a patient a selective estrogen receptor modulator (SERM), in combination with inhibiting ovarian secretions, e.g., by administering an LHRH agonist or antagonist. In some embodiments, a precursor of sex steroids, said precursor being selected from the group consisting of dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androst-5-ene-3β,17β-diol (5-diol), and androstenedione or a compound transformed into one of these, is also administered12-22-2011
20110312924NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS - Steroidal C-17 nitrogen-containing heterocycles of Formula I:12-22-2011
201202832291,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES - The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.11-08-2012
201301579897-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF - Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.06-20-2013
20130157991Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same - A drug product comprises a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.06-20-2013
20130184243COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH - Provided are compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.07-18-2013
20130190278Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases - The present invention relates to the use of the compounds of formula (I) and their pharmaceutically acceptable salts for the treatment or the prevention of ocular inflammatory diseases, in particular for the treatment and/or prevention of uveitis, severe conjunctivitis, dry eye syndrome or diabetic retinopathy.07-25-2013
20120015921PHARMACEUTICAL FORMULATIONS:SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.01-19-2012
20120028943Medicinal Cream Made Using Fluticasone Propionate And Chitosan And A Process To Make The Same - The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of fluticasone propionate, used in treating skin inflammation c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and a corticosteroid in the form of fluticasone propionate, are incorporated in cream base for use in treating skin inflammation due to allergy & itching & wounds on human skin involving contacting human skin with the above identified composition.02-02-2012
20120028942Medicinal Cream Made Using Neomycin Sulphate, Betamethasone Valerate, And Chitosan, And A Process To Make The Same - The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) a combination of active pharmaceutical ingredients (APIs), neomycin sulphate & betamethasone valerate used in treating bacterial skin infections & skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, a corticosteroid Betamethasone Valerate, and an antibacterial agent Neomycin Sulphate, are incorporated in cream base for use in treating bacterial skin infections and skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.02-02-2012
20120028941Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a MABA compound; an MPO inhibitor; a muscarinic antagonist; a PDE4 inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.02-02-2012
20120028940FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of azanitrile compounds as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.02-02-2012
20120028939SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS - The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof,02-02-2012
20120028938PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS - The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity,02-02-2012
20120028937CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Provided is a compound useful as a therapeutic drug for pain and inflammation caused by various pathological conditions such as neuropathic pain and rheumatoid arthritis. The compound of the formula (I) or a salt thereof [wherein R02-02-2012
20130196961COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - A combination which comprises (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.08-01-2013
20130196962NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.08-01-2013
20130196960Cannabinoid Receptor Agonists - The present disclosure relates to compounds useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders either alone or in combination therapy. The compounds have Formula (I), or are pharmaceutically acceptable salts thereof:08-01-2013
20120295878METHOD FOR THE TREATMENT OF CANCER - Provided is a method for determining the prognosis of cancer in a female patient with a solid tumor. The percentage of solid tumor cells expressing TUBB3 protein and the percentage of solid tumor cells expressing TUBB6 protein in a solid tumor sample from the patient is determined. Detection of TUBB6 protein expression in a percentage of solid tumor cells of the female patient that is less than the median percentage expression for TUBB6 protein and detection of TUBB3 protein expression in a percentage of solid tumor cells of the female patient that is less than the median percentage expression for TUBB3 protein indicates a patient with good prognosis; and wherein detection of TUBB6 protein expression in a percentage of solid tumor cells of the female patient that is equal to or greater than the median percentage expression for TUBB6 protein and/or detection of TUBB3 protein expression in a percentage of solid tumor cells of the female patient that is equal to or greater than the median percentage expression for TUBB3 protein indicates a patient with poor prognosis. Also provided is a method of sensitizing a cancer cell from a solid tumor from a male patient other than a prostate cancer cell to treatment with a chemotherapeutic agent comprising administering an effective amount of antiandrogen and a chemotherapeutic agent other than an antiandrogen. The antiandrogen may be administered before, after, or at the same time as the chemotherapeutic agent.11-22-2012
20130203716Inhaled Combination Therapy - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.08-08-2013
20130203714CHEMICAL COMPOUNDS - 643 - The invention concerns bicyclic compounds of Formula I08-08-2013
20130203715USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS - Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.08-08-2013
20120083479Compositions Comprising Azelastine and Methods of Use Thereof - The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.04-05-2012
20120094968SULFONIC AMIDE AND SULFOXIMINE-SUBSTTTUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF - The present application relates to novel sulfonamidw- or sulfoximine-substituted 1,4-diaryldihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.04-19-2012
20120094967COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISEASES - The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.04-19-2012
20120094966ORGANIC COMPOUNDS - The present invention relates to optionally substituted 3-amino-4,5-dihydro-(1H or 2H)-pyrazolo[3,4-d]pyrimidin-6(7H)-ones and their 4-imino or 4-thioxo derivatives, e.g., 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.04-19-2012
20130210784COMBINATIONS AND METHODS FOR TREATING NON AGE-RELATED HEARING IMPAIRMENT IN A SUBJECT - The present invention generally relates to treating non age-related hearing impairments. More specifically, the present invention provides combinations and methods for treatment and prevention of non age-related hearing impairment in a subject.08-15-2013

Patent applications in class With additional active ingredient